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Dominant mutations in the PRESENILIN genes PSEN1 and PSEN2 cause familial Alzheimer’s disease (fAD) that 
usually shows onset before 65 years of age. In contrast, genetic variation at the PSEN1 and PSEN2 loci does not 
appear to contribute to risk for the sporadic, late onset form of the disease (sAD), leading to doubts that these genes 
play a role in the majority of AD cases. However, a truncated isoform of PSEN2, PS2V, is upregulated in sAD brains 
and is induced by hypoxia and high cholesterol intake. PS2V can increase -secretase activity and suppress the 
unfolded protein response (UPR) but detailed analysis of its function has been hindered by lack of a suitable, 
genetically manipulable animal model since mice and rats lack this PRESENILIN isoform. We recently showed that 
zebrafish possess an isoform, PS1IV, that is cognate to human PS2V. Using an antisense morpholino 
oligonucleotide we can block specifically the induction of PS1IV that normally occurs under hypoxia. Here, we exploit 
this ability to identify the gene regulatory networks that are modulated by PS1IV. When PS1IV is absent under 
hypoxia-like conditions we observe changes in expression of genes controlling inflammation (particularly sAD-
associated IL1B and CCR5), vascular development, the UPR, protein synthesis, calcium homestasis, catecholamine 
biosynthesis, TOR signaling and cell proliferation. Our results imply an important role for PS2V in sAD as a 
component of a pathological mechanism that includes hypoxia / oxidative stress and support investigation of PS2V’s 
role in other diseases, including schizophrenia, when these are implicated in the pathology. 
 







Alzheimer’s disease (AD) is a neurodegenerative disorder with several pathological characteristics, including  severe 
neuronal loss, glial proliferation, extracellular deposition of senile plaques composed of amyloid-β, and deposition of 
intracellular neurofibrillary tangles (reviewed in [1, 2]). The overwhelming majority of AD cases are sporadic (sAD), 
with more than 15 million people affected worldwide. However, the cause(s) of sAD is poorly understood and 
therapeutic approaches are not yet well developed. 
 
The PRESENILIN1 (PSEN1) and PRESENILIN2 (PSEN2) genes are associated with the relatively rare, dominantly 
inherited form of AD, familial AD (fAD, reviewed in [3]). These genes encode transmembrane proteins embedded in 
the membranes of the endoplasmic reticulum (ER), Golgi, plasma membrane, endosomes and lysosomes [4]. 
Intriguingly, although the PRESENILIN proteins provide the γ-secretase enzyme activity that is critical for production 
of amyloid-β peptide (Aβ, regarded by many as central to pathological processes causing AD [5]) no genetic variation 
at the PSEN1 or PSEN2 loci has yet been discovered to contribute to the risk for developing sAD [6]. This, combined 
with the failure of γ-secretase inhibitors as AD-therapeutics and other observations inconsistent with the idea that A 
is a pathogenic agent, has encouraged a search for other changes in PRESENILIN gene function that may contribute 
to AD pathogenesis (reviewed in [7]). 
 
One PRESENILIN-related difference observed between normal and sAD brains is expression of a truncated isoform 
of PSEN2 protein, PS2V [8]. PS2V is produced by alternative splicing of PSEN2 transcripts that is induced 
specifically by hypoxia (see below). PS2V protein accumulates in intracellular inclusion bodies termed PS2V bodies. 
These are observed in pyramidal cells of the cerebral cortex and in the hippocampus of sporadic AD patients during 
early stages [9]. In vitro experiments indicate that PS2V protein impairs the unfolded protein response thereby 
sensitizing cells to various ER stresses and significantly stimulating the production of A40 and A42 peptides [9]. 
PS2V also changes the conformation of the protein tau, which is a major component of neurofibrillary tangles [10]. 





in sporadic AD brains (although the sample size was small [11]). This suggests that PS2V may play an important role 
in the pathogenesis of AD and other diseases in which hypoxia and oxidative stress are implicated. 
 
Using human neuoblastoma SK-N-SH cells, Sato et al. showed that the exclusion of exon 5 from PSEN2 transcripts 
to form PS2V mRNA is induced by hypoxia but not a number of other cellular stressors [9]. The oxidative stress 
produced by hypoxia induces expression of the protein HIGH MOBILITY GROUP AT-HOOK 1 isoform a (HMGA1a) 
in neurons and this binds to a sequence in exon 5 of PSEN2 transcripts. This interferes with spliceosome complex 
function causing exon 4 to be ligated to exon 6 and generating a frameshift that leads to a premature termination 
codon in exon 6 sequence [8]. Remarkably, although PS2V lacks critical amino acid residues required for -secretase 
catalysis, it nevertheless can increase -secretase activity and production of Aβ peptide from the A Precursor 
Protein (APP). To do this PS2V probably requires the presence of full-length PSEN protein [12]. Interestingly, the 
pathogenic K115Efx10 mutation of PSEN2 (causing fAD) truncates the open reading frame in a very similar position 
to the frameshift that generates PS2V [13, 14] and our previous analyses have shown that a peptide generated from 
K115Efx10 transcripts would have similar effects to PS2V on -secretase activity and the UPR [14]. This strongly 
supports that PS2V plays a role in development of sAD brain pathology. We recently documented that PS2V is not a 
uniquely human isoform but is widely conserved among most mammals although not in mice or rats [15]. Indeed, we 
showed that zebrafish possess a PS2V-cognate isoform, PS1IV, regulated by a conserved mechanism (i.e. involving 
a zebrafish orthologue of HMGA1a) but generated from the fish’s PSEN1 orthologous gene (psen1) rather than its 
PSEN2 orthologue (psen2). Thus, human PS2V and zebrafish PS1IV appear to share a common origin in an 
hypoxia-induced isoform of the ancestral PSEN gene that duplicated to form the contemporary vertebrate PSEN1 
and PSEN2 genes [14]. Like human PS2V, zebrafish PS1V can stimulate -secretase activity and suppress the 
unfolded protein response [14]. However, aside from these activities, we have no idea how this PRESENILIN isoform 






We recently demonstrated an ability to inhibit, specifically, the induction by hypoxia of the PS1IV isoform in zebrafish 
embryos. When embryos are placed in a sodium azide solution to mimic hypoxia, expression of Hmga1a is induced 
[20] but binding of this protein specifically to nascent psen1 transcripts can be inhibited by the presence of a 
morpholino antisense oligonucleotide that binds competitively to the Hmga1a binding site. This prevents the 
alternative splicing event that forms PS1IV mRNA under hypoxia while nevertheless allowing formation of 
translatable mRNA encoding full-length Psen1 protein [14]. Since so little is known regarding the function of PS1IV or 
its cognate human isoform PS2V, we exploited this ability to investigate changes in the zebrafish transcriptome 
caused by absence of PS1IV during hypoxia. We used a comprehensive microarray detecting zebrafish mRNAs to 
observe transcriptome-level changes in gene expression. These data were then subjected to various forms of genetic 
network analysis to reveal greater biological meaning from the observed expression changes. The results provide 
evidence supporting modulation by PS1IV of numerous processes that, in humans, are implicated in AD pathology 
and also in other diseases. In particular, PS1IV is required for upregulation of the IL1B gene that is a recognized AD 
risk locus and is central to neuroinflammation. Our results support that PS2V plays an important role in a pathological 







Materials and Methods 
 
Ethics statement   
 
All animal experiments including experiments on genetically modified organisms were conducted under the auspices 
of the University of Adelaide’s Animal Ethics Committee and Institutional Biosafety Committee. 
 
Zebrafish husbandry, morpholino injection and exposure to NaN3  
 
Danio rerio were bred and maintained at 28 °C on a 14 h light/10 h dark cycle. Embryos were collected from natural 
mating from Tubigen strain (Tu), grown in embryo medium (E3) and staged [16]. MoHmga1aBindBlock morpholino 
was synthesized by GeneTools LLC (Corvallis, OR, USA) and injected at 0.5mM (diluted to this concentration with 
MoCont as previously described [17]) at the one-cell stage. 
 
Sodium azide, NaN3, induces has previously been used for mimicry of hypoxia [18, 19] including in zebrafish [20, 21]. 
Exposure of embryos to NaN3 (Sigma-Aldrich CHEMIE Gmbh, Steinheim, Germany) was performed at 100μM from 6 
hours post fertilization (hpf) until embryos reached the developmental stage equivalent to that attained under 
normoxia at 48 hpf at 28.5 °C. 30 embryos were used for each treatment and replicate. 
 
Oligonucleotides 
The sequences of the microRNA primers and qPCR primers used in this study are given in Supplemental Data 1. 
The sequence of morpholino oligonucleotide MoHmga1aBindBlock was 5’- 
CTTGTAGAGCACCACCAGCACCAGG-3’. 
 






For microarray analysis, total RNA was extracted from batches of injected embryos using the RNeasy Mini Kit 
according to the manufacturer’s specifications (Qiagen GmbH, Hilden, Germany). For each sample, the RNA 
concentration was determined using a NanoVue™ UV–vis spectrophotometer (GE Healthcare Life Sciences, 
Fairfield, USA). RNA integrity and quality were then estimated using an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Palo Alto, CA) and the RNA integrity number (RIN) index was calculated for each sample. Only RNAs 
with a RIN number >7.0 were processed further.  
 
To evaluate genome-wide changes in gene transcription related to the presence or absence of PS1IV under mimicry 
of hypoxia, we performed hybridisation analysis using the Zebrafish Gene 1.0 ST Array (Affymetrix Inc. Santa Clara, 
CA). Briefly, 300ng of total RNA derived from embryos was converted to amplified sense strand cDNA using the 
Ambion WT Expression Kit (Life Technologies, Carlsbad, CA). The resulting sense cDNAs were fragmented and 
Biotin end labelled using the Affymetrix Genechip WT Terminal Labeling Kit prior to hybridisation to the arrays at 45 
°C for 16 hours. Finally, the signal intensity of the chip was scanned using a GeneChipR Scanner 3000TG and 
analysed using Expression Console software (www. Affymetrix.com) as described previously . Cell files were 
imported and intensities adjusted by RMA background correction and quantile normalization [22-24]. Each treatment 
had 4 biological replicates. The cell files which did not pass quality control were removed based on their quality 
assessments obtained by Expression Console reports. 
 
The final list of genes significantly (p≤0.05) over-expressed or under-expressed as a result of blocking PS1IV 
formation under hypoxia was generated using the following formula: 
 
Impact of PS1IV splicing blockage under hypoxia = [Comparison of (HMGA1aBindBlock) vs (Control Morpholino) 
under chemical mimicry of Hypoxia] – [Comparison of (HMGA1aBindBlock) vs (Control Morpholino) under Normoxia] 
– [Comparison of (Control Morpholino) vs (Uninjected) under chemical mimicry of Hypoxia] – [Comparison of (Control 






A Bayesian t-test using the FlexArray package (McGill University, Canada) was employed to find significantly over-
expressed and under-expressed genes (p≤0.05) for each of the dual comparisons in the above formula as previously 
described. Removal of genes with significant alteration in the control comparisons increases the reliability of 
discovery of genes influenced specifically by PS1IV expression.  
 
Gene ontology analysis was carried out using the “comparative GO” web application [25, 26]. 
 
Statistics-based subnetwork discovery and regulatory network analysis after loss of PS1IV under mimicry of 
hypoxia 
 
To understand the consequences of loss of PS1IV under hypoxia, we used the integrative approach of “gene set 
enrichment” (based on Fisher's exact test) [27] with union selected subnetworks [28]). This reveals significantly 
altered subnetworks as well as underlying regulatory mechanisms controlling alteration of gene expression patterns 




For determination of statistically altered subnetworks after loss of PS1IV splicing under mimicry of hypoxia, the 
following steps were performed: 
 
1- An enriched mammalian database of gene/protein/small RNA interactions, ResNet, was implemented in the 
Pathway Studio 10 package (Elsevier). ResNet is a database of biological relations, ontologies and subnetworks, 
compiled by Ariadne (Elsevier) for mammalian research (20, 21). One of the major advantages of this database is 
inclusion of information on the subcellular localization of gene products which provides the opportunity to evaluate 






A range of interaction sets are deposited in the ResNet  database such as regulation, expression, promoter binding, 
molecular transport, protein modification, binding, molecular synthesis, chemical reaction, direct regulation, miRNA 
effect, protein complex, and small molecule function. Furthermore, we updated the network database Pathway Studio 
10 using Medscan language programming via text mining [29] with the keywords of names of over-expressed and 
under-expressed genes after PS1IV loss of splicing, Alzheimer’s disease, and hypoxia to enrich the deposited 
networks in our reference database. MedScan is an NLP (Natural Language Processing) application for reading 
scientific literature and extracting protein-centric biological relations [29].  
 
2- Using as input the set of genes showing significantly altered genes expression after loss of PS1IV, different 
possible subnetworks to which these genes may contribute were called from the updated database of the Pathway 
Studio package.  
 
3- The gene set enrichment concept was used to distinguish and select important subnetworks. Gene set enrichment 
measures the enrichment of different subnetworks by an imported list of genes/miRNAs and highlights the statistically 
enriched subnetworks at p≤0.05, based on various statistical tests and particularly Fisher’s exact test [27]. As an 
example, if a particular subnetwork has 15 genes and 14 out of 15 genes of this subnetwork are present in the list of 
those displaying altered expression after loss of PS1IV, this subnetwork has a high probability of existence according 
to Fisher’s exact test. 
 
Integrative regulatory network construction 
 
For construction of an integrative regulatory network, various algorithms such as “add neighbours (with varying 
ranges of directly and indirectly interacting neighbours – “expansions” of 1, 2 or 3)”, “add direct interaction”, “add 







The add neighbours algorithm adds a new interacting element (direct or indirect interaction) to an imported gene 
entry if that new element is in within defined interacting range. Here, expansions of 1, 2, and 3 were tested. Add 
direct interaction only adds direct interactions to the imported gene list and produces the smallest networks. The next 
algorithm was the add shortest path algorithm. Two elements in the network may interact with each other via many 
different routes. The add shortest path algorithm selects the shortest route as that is the most probable to occur. The 
add common targets algorithm searches for interactions that are affecting a shared target. Add common regulators 
looks for common regulators of imported genes such as transcription factors. Union selected subnetworks is a 
reliable algorithm which attempts to join together statistically significant subnetworks (from the previous stage of 
subnetwork discovery) and finds the underlying relationship between subnetworks based on the shared elements. 
Due to the ability of transcription factors (TFs), ligands, and microRNAs, to regulate multiple systems, it can be 
expected that these play central roles in joining various subnetworks. In fact, union selected subnetworks can be 
seen as a crosstalk discovery tool. 
 
Topological analysis of regulatory networks 
 
Topological analyses of the regulatory networks of over-expressed, under-expressed as well as the combined set of 
over- and under-expressed genes (constructed using union selected subnetworks) were performed using the cyto-
Hubba package [34] in Cytoscape software [35].  Centrality indices including Degree, clustering coefficient, Edge 
Percolated Component (EPC), Maximum Neighbourhood Component (MNC), Density of Maximum Neighbourhood 
Component (DMNC), Maximal Clique Centrality (MCC) and centralities based on shortest paths, such as Bottleneck 
(BN), EcCentricity, Closeness, Radiality, Betweenness, and Stress were used to identify the highest-ranked genes 
(hubs) in the structure of the regulatory networks using the cyto-Hubba plugin [34, 36]. For details regarding the 
employed indices, please see the cyto-Hubba URL: http://hub.iis.sinica.edu.tw/cytoHubba/supplementary/index.htm. 
The genes which received the highest scores in the above mentioned indices were selected as the highest-ranked 





in Cytoscape for the regulatory networks of over-expressed and under-expressed genes, and for the combined set of 
over- and under-expressed genes. 
 
Validation of network nodes by quantitative real-time PCR (qPCR)  
 
The relative standard curve method for quantification was used to determine the expression of experimental samples 
compared to a basis sample. For experimental samples, target quantity was determined from the standard curve and 
then compared to the basis sample to determine fold changes in expression. Gene specific primers were designed 
for amplification of target cDNA and the cDNA from the ubiquitously expressed control gene eef1a1l1. The reaction 
mixture consisted of 50ng/μl of cDNA, 18 μM of forward and reverse primers and Power SYBR green master mix 
PCR solution (Applied Biosystems Foster City, CA, USA). 
 
To generate the standard curve, cDNA was serially diluted (100 ng, 50 ng, 25 ng, 12.5 ng). Each sample and 
standard curve reaction was performed in triplicate for the control gene and experimental genes. Amplification 
conditions were 2 min at 50 °C followed by 10 min at 95 °C and then 40–45 cycles of 15 s at 95 °C and 1 min at 60 
°C. Amplification was performed on an ABI 7000 Sequence Detection System (Applied Biosystems) using 96 well 
plates. Cycle thresholds obtained from each triplicate were averaged and normalized against the expression of 
eef1a1l1. Each experimental sample was then compared to the basis sample to determine fold changes of 
expression. For each gene, 3 biological replicates and 3 technical replicates were used in qPCR. 
 
Validation of predicted miRNAs by quantitative real-time PCR (qPCR)  
 
MicroRNA PCRs were performed on replicated biological samples using TaqMan microRNA assays (Life 
Technologies). Briefly, a multiplex cDNA reaction was performed on 10ng of RNA using a TaqMan MicroRNA 
Reverse Transcription Kit together with specific TaqMan microRNA assay primers (Life Technologies). Real-time 





Universal Mastermix (Life Technologies) on a Rotorgene 6000 series PCR machine (Corbett Research). The relative 
expression of microRNA was calculated using the comparative Ct method with U6 as the endogenous reference. A 







In the work described below, we used microarray analysis to assess changes in the expression of genes when PS1IV 
expression is blocked during hypoxia-like conditions in zebrafish embryos. However, since numerous human genes 
have “co-orthologues” in zebrafish (due to a whole genome duplication that occurred early in the teleost evolutionary 
lineage [37], and since the GO and Pathway Studio databases contain predominantly mammalian genetic 
information, we refer to genes using their human orthologue names. Raw microarray expression data gene 
designations are given in Supplemental Data 2 and 3. 
 
Genes with altered expression after failure to form PS1IV under hypoxia 
 
PS2V is a truncated isoform of PSEN2 that shows elevated expression in the brains of people with sporadic AD. 
However, the cellular role of PS2V cannot be investigated using mouse or rat models since the rapid evolution of 
some of their AD-related genes has resulted in loss of their ability to induce this isoform [15]. In contrast, zebrafish 
produces a PS2V-cognate isoform named PS1IV [37]. We can block induction of PS1IV in embryos subjected to 
hypoxia by injection of the morpholino oligonucleotide Hmga1aBindBlock [14]. Since so little is known about PS2V 
function, we exploited this phenomenon to investigate the effects on cellular function of loss of PS1IV under hypoxia 
using gene network analysis of relative expression data from microarrays. 
 
Zebrafish embryos were injected at the 1-cell stage with MoHmga1aBindBlock or the negative control morpholino 
MoCont. They were then incubated in 100 µM sodium azide, NaN3 to mimic the effects of hypoxia (a treatment 
hereafter referred to simply as “hypoxia”) from 36 hpf to 48 hpf before extraction of mRNA and analysis of relative 
gene expression on the Affymetrix Zebrafish Gene 1.0 ST Array. A number of control microarray comparisons were 
also made to identify genes for which expression is affected by the act of injection or by the non-specific effects of the 
presence of morpholino oligonucleotides (Figure 1). Any genes for which expression was significantly altered by 






Bayesian t-tests produced lists of genes with significantly increased or decreased transcript levels (“expression”) in 
our microarray comparisons. We describe these genes below as either “over-“ or “under-expressed” in response to 
loss of PS1IV under hypoxia. The final list of genes with significant (p≤0.05) over- or under-expression was 
generated after removal of any genes showing significantly altered expression in the controls (see Figure1, Table 1, 
Supplemental Data 2 and Supplemental Data 3). 
 
Among the genes showing over-expression under hypoxia without PS1IV (i.e. genes that would normally be 
repressed by the formation of PS1IV) were numerous genes involved in modulation of immune responses (HRH2, 
IL17RA, CD22, ACY1, IRF4, XCL2 etc.), in regulation of TOR signalling (RICTOR, PKD1), in regulation of blood 
pressure and formation of vascular structures (e.g. AGTR1 and ANGPTL2), and in cell proliferation (PIM3, ACY1, 
OLFM4) (Supplemental Data 2). This set of genes also included two genes known to be involved in neurological 
conditions, GAK (associated with Parkinsons Disease) and CAMTA1 (associated with cerebellar ataxia, 
nonprogressive, with mental retardation (Supplemental Data 2). Two non-coding RNAs were also seen in the list of 
genes over-expressed in the absence of PS1IV, si:dkey-167i21.2 and si:ch73-110p20.1. 
 
A greater number of genes were identified as showing significant under-expression under hypoxia without PS1IV (i.e. 
genes that are normally dependent on PS1IV for stable or increased expression under hypoxia). These included 
genes encoding transcription factors or proteins involved in chromatin remodelling (e.g. NKX3-2, SRCAP, GBX2, 
TCF25, SMARCA4, POU4F2), genes involved in ER function (CALR), intracellular signalling (OCRL, AIDA, 
PLEKHA4, PLCB1, MAPKAPK5) and a considerable number of ribosomal proteins (see Table 1).  
 
An overview of our genetic network analysis of transcriptome changes occurring due to failure to form the 






Gene regulatory network analysis offers a more comprehensive level of understanding of biological mechanisms 
compared to analyses of individual (separate) gene expression changes. 
 
Within cells, the transcripts and proteins encoded by genes can have many functionally interacting partners. 
“Subnetworks” are sets of genes with biologically important interactive relationships. The Pathway Studio 10 software 
package (based on the Fisher Exact Test) accepts a set of genes with significantly altered expression and evaluates 
the genes with respect to their contribution to all the possible subnetworks in its database. It then ranks these 
subnetworks in terms of statistical significance to create a list of “statistically significant subnetworks”. We used the 
Pathway Studio 10 software package to examine the sets of genes showing significantly increased or decreased 
transcript levels when formation of the PS1V isoform is blocked during hypoxia. Subnetworks with a statistical 
significance of p≤0.05 were then ranked. 
 
Once ranked lists of statistically significant subnetworks had been determined, we then used the algorithm “union 
selected subnetworks” to attempt to join different subnetworks into larger aggregate networks (integrative networks). 
Networks were produced based on the set of genes with significantly increased transcript levels, the set of genes 
with significantly decreased transcript levels, and the set of all genes with either significantly increased or decreased 
transcript levels (see later). The union selected subnetworks algorithm looks for elements shared between 
subnetworks that could act as links between them. This procedure is valuable as a test of the veracity of the 
existence of the subnetworks identified within our experimental system since subnetworks that show greater numbers 
of shared elements are less likely to be spurious. 
 
A number of other methods for network analysis were also applied to our sets of genes that are “over”- and ”under”-
expressed in the absence of PS1IV. These other methods are summarised in the Materials and Methods section. In 
general, these analyses confirmed the major features of the networks produced by union selected subnetworks 
analysis. Of all the methods used, “union selected subnetworks” proved to be the most efficient network prediction 





(transcription factors, microRNAs, and ligands). The veracity of the networks predicted by union selected 
subnetworks was confirmed by qPCR analysis of predicted changes of transcript levels for a number of genes 
identified as nodal within the networks (see the section “Validation of network nodes (hubs) by RT-qPCR” below and 
Figure 2). In the description that follows we have focused on the union selected subnetworks analysis since it is the 
method producing the most statistically rigorous output. (The union selected subnetworks algorithm has also been 
recently used in the discovery of transcriptomics-based regulatory networks of biological phenomena such as 
apoptosis and stem cell differentiation [31, 32, 38]). 
 
Significant subnetworks formed by genes over-expressed after failure to form PS1IV under hypoxia  
 
Genes over-expressed after failure to form PS1IV under hypoxia were examined for their contribution to formation of 
statistically significant subnetworks (p≤0.05) based on the “gene set enrichment” approach [27] using the Pathway 
Studio 10 software package. The identified significant subnetworks and their corresponding p-values are presented in 
Table 2. The genetic relationships underlying each subnetwork and citations upon which these relationships are 
based are presented in Supplemental Data 4. The subnetworks are: neighbours of GABARAP (Gamma-Aminobutyric 
Acid Receptor-Associated Protein), PDLIM5 (PDZ And LIM Domain 5), MIR20A (microRNA 20a), LPS 
(lipopolysaccharides), BTK (Bruton A gamma globulinemia), and NOTCH2 (notch2). These subnetworks and their 
interactions (relationships) are visualised in Figure 3. The gene GABARAP encodes a ligand-gated chloride channel 
that mediates inhibitory neurotransmission and interacts with the cytoskeleton. GABARAP protein has a direct 
regulatory effect on the angiotensin receptor AGTR1 that regulates blood pressure and vascular development. 
GABARAP also mediates membrane expression of AGTR1 (Figure 3A) [39]. Interestingly (and with relevance to AD), 
GABARAP is also involved in apoptosis and autophagy [40-45]. As presented in Figure 3B, PDLIM5 may be involved 
in the observed over-expression of AGTR1 and another gene, PKD1, after loss of PS1IV [46, 47]. PDLIM5 has been 
implicated in bipolar disorder, depression, and schizophrenia via regulation of dendritic spine morphogenesis in 
neurons [48, 49]. This is especially interesting when one considers that the human homologue of PS1IV, PS2V, is 





plays an important role in heart development and cardiomyocyte expansion [50]. Since mutations in both human 
PSEN1 and PSEN2 can cause Dilated Cardiomyopathy (DC) this suggests that the PRESENILIN genes together 
with PDLIM5, PKD and AGTR1 may form a genetic network involved in cardiovascular disease.  
 
One subnetwork is formed by NOTCH2 together with FOXE3. NOTCH genes encode transmembrane receptors that 
signal directly to the nucleus. When NOTCH receptors are cleaved by PSEN proteins within -secretase complexes, 
their intracellular domains move into the nucleus to act as transcription factors [51]. NOTCH receptors have important 
roles in maintenance of undifferentiated stem cell states, particularly under hypoxic conditions [52, 53]. During 
zebrafish embryo development, the gene foxe3 is expressed mainly in the developing lens of eyes that are relatively 
much larger than in humans. The foxe3 gene also shows restricted expression in the brain and in the hatching gland 
[51], a structure not found in mammals. This reminds us that our microarray analysis involves all the cells of a 
developing zebrafish at 48 hpf and not only those with relevance to the brain. This means that the networks we 
subsequently identify should not be interpreted as representing single overall regulatory networks within a single cell 
type. Some of the subnetworks will exist only within particular cell types and some apparent linkages between 
putative subnetworks may be artefactual. 
 
A subnetwork illustrating the ability of microRNAs to coordinate regulation of multiple gene transcripts is formed by 
the apparent inhibitory effect of the microRNA MIR20A on PKD1, AGTR1, and CAMTA1 (Figure 3C). Since these 3 
genes are over-expressed in the absence of PS1IV, we would predict MIR20A to be downregulated in this 
circumstance. MIR20A expression is not measured by the Affymetrix Zebrafish Gene 1.0 ST Array but subsequent 
qPCR analysis of its expression under normoxia and mimicry of hypoxia in the presence or absence of PS1IV 
supports that PS1IV may be important for maintaining levels of MIR20A expression under hypoxia (Figure 4). 
MIR20A belongs to the miR-17 microRNA precursor family that includes miR-20a/b, miR-93, and miR-106a/b. These 
microRNAs negatively regulate gene expression through complementarity to the 3' UTR of specific target messenger 






From our analysis, another microRNA, MIR1-1, is implicated in a putative subnetwork regulating NOTCH2 and GAK 
(Figure 3F). Decreased NOTCH signaling has been suggested to underlie the development of AD pathology [54] so 
the downregulation of NOTCH2 by PS1IV under hypoxia may be significant. Decreased expression of CYCLIN G-
ASSOCIATED KINASE, GAK has been shown to inhibit NOTCH signaling and to increase neural cell death in 
zebrafish [55]. GAK has also been associated with Parkinson Disease (PD) in genome wide association studies 
(GWAS) [56], consistent with its interaction with the PD-associated protein –synuclein [57]. Previously, we 
observed increased expression of cyclin G2 gene expression when zebrafish psen1 or psen2 activity was 
suppressed in embryos in a morpholino-based study [58]. We have also argued that insufficient delivery of oxygen to 
the brain may play an important role in AD pathogenesis [59] and, in this light, it is interesting that both the MIR1-1- 
and MIR20A-coordinated subnetworks described here involve genes important for vascular function and 
development (e.g. see [60] and [61]). The analysis summarised in Figure 5 also illustrates that both these 
subnetworks are potentially linked through the transcription factor ESTROGEN RECEPTOR 2, ESR2. The ESR2 
gene shows homology to the Hairy/enhancer of split (HES)-related genes that are typically directly activated by 
NOTCH signaling. Also, the estrogen molecule estradiol has been shown to up-regulate Agtr1 in rat heart [62] .  
 
 
Finally, lipopolysaccharides are known to have positive regulatory effects on all the receptors seen to be over-
expressed after loss of PS1IV (AGTR1, HRH2, IL17RA, CD22, and NOTCH2) [63-65]. Together these form a 
statistically significant subnetwork (Figure 3D). Lipopolysaccharides commonly induce inflammatory responses  [66] 
while hypoxia (that induces PS2V and PS1IV formation) is also pro-inflammatory. The fact that PS1IV upregulates 
expression of the pro-inflammatory cytokine IL1B and the chemokine receptor CCR5 (see later) suggests that the 
truncated PRESENILIN transcript isoforms induced by hypoxia act as important modulators of inflammatory 
responses.     
 






Transcription factors and microRNAs commonly establish the crosstalk and coordination between different regulatory 
subnetworks since any one transcription factor or microRNA usually has the ability to regulate multiple gene 
transcripts. To detect potentially coordinated subnetworks, genes significantly over-expressed after failure to form 
PS1IV under hypoxia were subjected to various network construction algorithms including “add interacting 
neighbours (interacting range of 1, 2, and 3, as mentioned in Material and Methods)”, “add direct interaction”, “add 
shortest path”, “add common targets”, “add common regulators”, and “union selected subnetworks”.  
 
Figure 5 shows the network generated when the union selected subnetworks algorithm was applied to the list of 
statistically significant subnetworks given in Table 2. Significant features of this network are described below. Also, 
Supplemental Data 5 demonstrates the underlying relationships of the network. 
 
The transcription factor encoded by ATF2 (also known as CREBP1) regulates PKD1 and ANGPTL2 within this 
network. Loss of ATF2 has been shown to affect mouse Psen1 expression and to cause cranial motoneuron 
degeneration during brain development [67]. The ATF2 protein is involved in regulation of cellular responses to 
numerous stresses [68]. The role of MIR20A as a key subnetwork coordinator controlling expression of CAMTA1, 
AGTR1 and PKD1 is evident (see below and Figure 5). The CAMTA1 and AGTR1 genes are described above but 
PKD1 encodes a protein that has been observed in astrocytes and has been shown to activate the JAK-STAT 
signaling pathway [69]. Another microRNA suggested to coordinate a subnetwork, MIR1-1 (see above) regulates 
NOTCH2 and MRC2 receptor expression and expression of GAK in the Golgi apparatus. In the network analysis, the 
number of interactions for any gene product can be used as an index of that gene’s regulatory importance. The 
structure of our network of genes over-expressed after failure to form PS1IV highlights the products of PKD1, 
AGTR1, ANGPTL2, and NOTCH2 as central regulatory elements since these each show large numbers of 
interactions.  
 
The results of an alternative strategy for network assembly – the shortest path method – are presented in 





nodes. Calmodulin has a considerable number of interactions within that network. Noticeably, CAMTA1 expression is 
under the control of many microRNAs, such as mir20A and mir34A emphasing both its functional importance and the 
selective pressure for its tight regulatory control. This is not unexpected when one considers the important role that 
Ca2+ signaling and the PRESENILIN proteins play in interactions between the ER and mitochondria [70, 71]. 
CAMTA1 encodes a Ca2+-regulated transcription factor and changes in CAMTA1 expression have been associated 
with early-onset nonprogressive cerebellar ataxia and mild mental retardation [72-74]. The relationships within this 
network are presented in Supplemental Data 7. 
 
Decreased expression of MIR20A after loss of PS1IV under hypoxia  
 
In network analysis, a “seed” is defined as the central gene (node) in a subnetwork if it has the highest number of 
interactions with other subnetwork members. As seen in Figures 3 and 5, MIR20A is the seed of an interesting 
subnetwork which negatively modulates expression of important genes that are over-expressed after failure to form 
PS1IV. These genes include PKD1, AGTR1, and CAMTA1. We have analysed the expression of MIR20A in the 
presence and absence of PS1IV under hypoxia in zebrafish (Figure 4). Interestingly, the expression of MIR20A 
appears to be decreased after loss of PS1IV (by 1.6 fold on average although p is only 0.1). As microRNAs bind to 
the mRNA of target genes to decrease their expression it is expected that down–regulation of MIR20A will result in 
up-regulation of its targets in the network, i.e. PKD1, AGTR1, and CAMTA1. 
 
It should be noted that changes in the expression levels of some microRNAs can cause disproportionately greater 
changes in the expression of their target mRNAs. This is because microRNAs can function at much lower 
concentrations than mRNAs and need not be translated before binding to mRNAs to rapidly affect gene expression. 
Therefore, typically a fold change of 1.2 – 1.5 is used as a lower threshold when identifying microRNA s with altered 
expression [75, 76]. 
 






When formation of PS1IV is suppressed during hypoxia, a number of genes show decreased expression. These 
genes require PS1IV for normal or increased expression during chemical mimicry of hypoxia and are listed in Table 
1. We used these genes to construct subnetworks using the Pathway Studio 10 software (as described above for 
those genes with increased expression in the absence of PS1IV). 
 
Significant subnetworks generated using the under-expressed genes are shown in Table 3 and Figure 6. Many of the 
subnetworks are related to apoptosis and immune response, including genes such as CASP5, NLRP12, IL1B, 
TRIM22 and CCR2. The underlying relationships of these subnetworks are presented in Supplemental Data 8. It is 
apparent that IL1B is shared in many subnetworks. The regulatory subnetwork with the greatest significance 
(smallest p-value) is controlled by the transcription factor MEF2D (myocyte enhancer factor 2D) (Figure 6C). MEF2D 
is a stress-induced gene involved in cardiac muscle development as well as neuronal differentiation and survival. 
MEF2D plays diverse roles in cell growth, survival and apoptosis via the p38 MAPK signaling pathway. It has been 
suggested that MEF2D is a critical protein in the regulation of neuronal apoptosis and autophagy [77-80]. Another 
important subnetwork coordinates around Ca2+ ion concentration (Figure 6D) again emphasizing the relationship 
between PRESENILIN gene function and this ion. 
 
Prediction of a regulatory network coordinating genes under-expressed after failure to form PS1IV  
 
A regulatory network for under-expressed genes was constructed based on the union selected subnetworks 
algorithm as discussed above. This network is presented in Figure 7 and its underlying relationships are given in 
Supplemental Data 9. A variety of cellular organelles and structures respond to modulation by PS1IV including the 
mitochondrion, endoplasmic reticulum, Golgi apparatus, nucleolus, and plasma membrane emphasing the functional 






The following nodes are central in the generation of the regulatory network of under-expressed genes: (1) IL1B, (2) 
CCR5, (3) TH, (4) CALR, (5) SMARCA4 and (6) MEF2. According to the Gene Ontology classification of CCR5 and 
based on our ComparativeGO database [25, 26], this gene, CCR5 is involved in aging and promotion of apoptosis. 
CCR5 has previously been suggested to have a modulatory effect on the activated microglia seen in AD brains [81] 
and its expression is elevated in peripheral blood mononuclear cells [82] and in other cells of the immune system in 
AD patients [83]. In rats, CCR5 is expressed by microglia in the developing brain and predominantly in the 
endothelial cells of the adult brain [84]. It is highly up-regulated in the brain by hypoxia/ischaemia supporting that 
hypoxia is an important element of AD pathology [84]. However, some researchers have reported that hypoxia can 
inhibit upregulation of CCR5 in mouse macrophages [85]. 
 
As can be seen in Figure 7, TH and IL1B represent intensive nodes in the network. TH encodes the enzyme 
TYROSINE HYDROXYLASE that is rate limiting in the catecholamine biosynthetic pathway required for production of 
dopamine. Interestingly, hypoxia is known to regulate TH activity in selected areas of the brain [86]. It has recently 
been documented that disruption of TH activity in humans causes Segawa syndrome, an inherited form of infantile 
Parkinsonism [87, 88]. TH has also been seen to modulate the release of inflammatory cytokines so the observed 
coupling of the TH and IL1B nodes (below) in our network is not unexpected. Also intriguing is the existence of 
another gene associated with Parkinson disease as a node in our network, LRRK2. Mutations in LRRK2 are one of 
the most common causes of familial Parkinson disease. The protein product of LRRK2 binds to the product of the 
TUBULIN, BETA gene, TUBB, that is the most under-expressed gene when PS1IV is absent under hypoxia. LRRK2 
has also been seen to stimulate protein expression by acting on Argonaut proteins to repress microRNA action [89].  
 
Cytokines are signaling compounds and major mediators of immune responses which are involved in stress 
responses, cell differentiation, and apoptosis. The IL1B protein is a member of the interleukin 1 cytokine family which 
is proteolytically processed to its active form by CASPASE 1 (CASP1/ICE). The importance of IL1B in sporadic AD is 
demonstrated by identification of polymorphisms at this gene locus associated with increased AD risk [90].  IL1B 





genetic network. Thus PS1IV contributes significantly to induction of IL1B expression under hypoxia. In our network, 
IL1B communicates with CCR5 the product of which has important roles in mediation of neuroinflammatory 
responses to excitotoxicity (see above and [91]). Our predicted network also shows the transcription factor encoded 
by STAT4 as increasing the expression of CCR5 and IL1B. STAT4 protein is well recognized as playing a stimulatory 
role in inflammation including in the brain [92].  
 
The family of MEF transcription factors figures prominently in our network of under-expressed genes. These 
transcription factors control neuronal survival, apoptosis, and autophagy [79, 80]. We also see involvement of the 
gene encoding CREATINE KINASE, MITOCHONDRIAL 1B, (CKMT1B), a protein of the inner membrane of 
mitochondria involved in lipid transfer between membranes. The gene CALR, that encodes a stress response protein 
binding Ca2+ ions in the ER and that is also found in the nucleus possibly acting as a transcription factor [93] is an 
important node in this network. Interestingly, in the ER, CALR binds to PROGRANULIN, (a protein implicated in 
frontotemporal dementia), where it  forms a complex together with protein disulfide isomerases [94]. The 
mitochondrial associated membranes (MAM) are foci for oxidative protein folding (disulphide bond formation) and are 
a major subcellular location for PRESENILIN protein expression [95]. Changes in PRESENILIN expression affect the 
lipid constitution of the MAM that is a site of oxygen use and that produces high levels of reactive oxygen species 
(ROS). ROS induces expression of PS2V via upregulation of HMGA1a to alter PSEN2 transcript splicing [20]). 
Numerous mutations in PSEN1 are linked to frontotemporal dementia (usually in association with AD). Thus, our 
network analysis supports involvement of the PSEN proteins in frontotemporal dementia via regulatory interactions 
with PROGRANULIN in the MAM under hypoxic conditions. 
 
SMARCA4 is another node in the network (Figure 7). SMARCA4 encodes a calcium signaling related protein with 
helicase and ATPase activities that can regulate the expression of genes by altering their chromatin structure [96]. 






MAPKAPK5, encoding a protein of the serine/threonine kinase family, governs another node in the network. This 
kinase is expressed in response to cellular stress and proinflammatory cytokines [98, 99]. As a tumor suppressor 
protein, the major functions of MAPKAPK5 are activation of apoptosis and mediation of senescence [100]. 
Interestingly, MAPKAPK5 is also involved in amyloidosis and yellow fever diseases [101]. This supports the idea that 
PS2V might be important for the accumulation of amyloid in AD (e.g. through its suppression of the UPR, [9, 14]). 
 
In our network of under-expressed genes, the microRNAs MIR137 and MIR26A1 potentially negatively regulate the 
nodal gene, PHOSPHOLIPASE C, BETA-1, (PLCB1), that encodes a key protein regulating signal transduction 
pathways involving IP3 and diacylglycerol. Deletions of PLCB1 have been observed in the brains of people with 
schizophrenia [102] which may be significant since PS2V has also been observed to be greatly elevated in 
schizophrenia brains [11]. This supports that neural hypoxia may be an important environmental influence in 
schizophrenia [103] via PS2V. 
 
Finally, a considerable number of genes encoding ribosomal proteins are under-expressed in the absence of PS1IV, 
for example RPL9, RPS15A, RPL28, RPL26 and RPS19. The stimulation of expression of these proteins by PS1IV 
under hypoxia appears consistent with the action of this truncated PRESENILIN protein and its cognate PS2V 
isoform to repress the UPR [104]. The UPR usually acts to suppress protein synthesis when cellular stresses (e.g. 
lack of oxygen for oxidative protein folding) lead to increased levels of unfolded proteins [104]. As mentioned above, 
the stimulation of LRRK expression by PS1IV is also consistent with its opposition to the UPR since this should 
increase protein synthesis. Notably, among the genes normally suppressed by PS1IV expression, the gene with most 
significantly altered expression is HSPA8 encoding the chaperone HEAT-SHOCK 70-KD PROTEIN 8. Upregulation 
of chaperone protein expression is an important element of the UPR. However, the action of PS1IV on other UPR 
actors is less easy to explain. PS1V stimulates CALR expression (see above), the product of which is involved in the 
UPR and is normally upregulated by ER stress [105]. The CALRETICULIN protein can form complexes with the Ca2+ 
pump ATPase, Ca(2+)-TRANSPORTING, FAST-TWITCH 1 (ATP2A1, also known as SERCA) and disulphide 





upregulated by unfolded protein stress [107]. Indeed, the PRESENILIN1 holoprotein has been observed to act a 
chaperone [108, 109]. 
 
Topological analysis of regulatory networks 
 
To identify those genes central to the structure of the regulatory networks, Bottleneck, DMNC, MNC and MCC 
centrality indices were calculated. The results are presented in Supplemental Data 10 and the genes are ranked 
based on overall scores of importance in various indices. Also, the 10 highest-ranked genes according to Bottleneck 
are presented in Figure 8.  
 
AGTR1, NOTCH2, LPS, are PKD1 are central hubs in the network structure of genes over-expressed after failure to 
form PS1IV under hypoxia (Supplemental Data 10). MIR20A received a high rank in network topological indices 
(Supplemental Data 10, Figure 8) 
 
The Inflammatory response genes IL1B and CCR5 are central in the regulatory network of genes under-expressed 
after failure to form PS1IV under mimicry of hypoxia (Supplemental Data 10). Also, STAT4, a transcription factor 
involved in stimulation of brain inflammation [92], forms a hub in this network (Supplemental Data 10, Figure 8). 
 
The raw expression value within different biological replicates of the treatments in this study is presented in 
Supplemental Data 11. Low standard deviations within different biological treatments show that gene expression is 
consistent across the biological replicates of each treatment. 
 
In the regulatory network constructed from the combined set of over- and under-expressed genes after loss of PS1IV, 
the highest ranked genes (hubs) were: IL1B, TH, LPS, CCR5, AGTR1, HSPA8, PKD1, CALR, and MAPKAPK5. Ca2+ 
was also identified as a hub. Overall, the topological analyses support the importance of these genes/factors in the 






A global regulatory network of both over- and under-expressed genes after failure to induce PS1IV during 
hypoxia 
 
The genes observed to be over- or under-expressed in our study were detected after a only one form of experimental 
manipulation, i.e. blockage of PS1IV expression under hypoxia. Therefore, we can expect both the over- and under-
expressed genes to show regulatory interactions within a global network.  To examine this, the combined set of over- 
and under-expressed genes was subjected to subnetwork discovery using the “gene set enrichment” approach 
followed by integrative network construction using the union selected subnetworks algorithm. Supplemental Data 12 
shows the subnetworks enriched by this global gene set. The network underlying these genes regulated by PS1IV is 
presented in Supplemental Data 13 and its constructing relationships in Supplemental Data 14.  
 
The combined, global network does not reveal very significant new nodes but does highlight the intensity of the nodal 
roles played by IL1B, PLCB1, NOTCH2, AGTR1, SMARCA4, CALR, PKD1 and HSPA8.  The regulation by PS1IV of 
processes in the ER, mitochondrion, nucleus and on the plasma membrane is evident.  The contribution of the ER 
and mitochondrial dysfunction to induction and progression of AD has been discussed recently [108, 110, 111]. Our 
results support that PS2V may play a significant role in this. 
 
Validation of network nodes (hubs) by RT-qPCR  
 
Finally, to confirm the validity of our constructed networks, RT-qPCR was performed for a subset of those genes 
located at network nodes (Figure 2). The results showed high correspondence between the microarray and RT-qPCR 
results. CAMTA1 showed more than a 2-fold increase in mRNA level in both microarray and qPCR analyses. On the 
other hand, IL1B was down regulated by more than 2-fold in both analyses. Both methods of analysis showed PKD1 
to be significantly over-expressed after inhibition of PS1IV formation under hypoxia while MAPKAPK5 and SMARCA4 






Several factors have inhibited analysis of the correspondence between changes in mRNA expression and 
consequent protein expression changes. There is a dearth of commercially available antibodies that detect zebrafish 
proteins and proteomic analyses of zebrafish embryos can be problematic due to interference from the high levels of 
yolk vitellogenins present at these stages [112]. Hopefully, the results of our analyses will direct future proteomic 
experimentation in cultured human cells that will support our findings. 
 
Literature mining-based network analysis of under-expressed genes after failure to form PS1IV highlights 
PS1IV’s involvement in cancer and cardiomyopathy 
 
During our construction of various networks, one was of particular interest. By using the shortest path algorithm to 
analyse genes under-expressed after failure to form PS1IV and by incorporating disease terms (to extract 
relationships between these genes and different diseases from the scientific literature, see Material and Methods) we 
identified a network that emphasizes the pathological importance of changes in expression of IL1B, HSPA8, TH and 
CALR (see Supplemental Data 15 and Supplemental Data 16). This suggests that PS1IV’s human homologue, 
PS2V, may play roles in the progression of cancer and in preeclampsia. Changes in the expression of the under-
expressed genes TH, IL1B, PLCB1 and AMPD1 are also associated with heart failure. This is interesting since 










Despite their importance as fAD loci, genome-wide association studies have failed to identify the PRESENILIN genes 
as risk loci in the predominant, late onset form of AD, sAD. This has raised concern that the pathological 
mechanisms underlying these two forms of AD may differ. However, a particular isoform of PSEN2 upregulated by 
hypoxia [8] and high cholesterol [15], PS2V, shows increased expression in sAD brains. Therefore it is important to 
understand the role this isoform plays in gene regulation. Investigation of PS2V function in the genetically 
manipulable rodent models is thwarted by the accelerated evolution of the fAD genes in these animals and their 
consequent loss of ability to express PS2V [114]. However, the ability to express this isoform in response to hypoxia 
has been retained by zebrafish and the molecular mechanism controlling induction of zebrafish PS1IV and human 
PS2V under hypoxia is conserved [14].We have also previously observed that the pathological function of the 
PRESENILIN genes cannot be correctly understood in physiologically abnormal systems [14]. Our ability to inhibit 
specifically the induction of the endogenous PS1IV isoform under hypoxia-like conditions in developing zebrafish 
embryos enables us to examine its function in an otherwise normal cellular state (in contrast to the abnormal cell 
types and growth conditions commonly involved in studies using tissue culture). 
 
Aside from the abilities of PS2V / PS1IV to suppress the UPR and stimulate -secretase activity, nothing is known 
regarding the function of this isoform, why this function has been conserved over nearly half a billion years since the 
tetrapod/teleost divergence, or why this isoform was lost from the rodent family Muridae but not other rodents or 
mammals [14]. Disconcertingly, our results show that this isoform regulates expression of a number of genes and 
cellular systems associated with a variety of neurodegenerative conditions including AD (see below), Parkinson 
disease (e.g. LRRK2, TH and GAK), schizophrenia (e.g. PLCB1, PDLIM5), early-onset nonprogressive cerebellar 
ataxia (CAMTA1) and others. This reinforces concerns that mouse models of Alzheimer’s disease and other 






Our microarray analysis has shown that loss of PS1IV function in zebrafish embryos under hypoxia-like conditions 
significantly alters the expression of a number of genes implicated in AD pathology in humans. We have listed a 
number of these genes in this paper but a greater depth of analysis is required in order to understand the changes in 
cell biology that these gene expression changes represent. Gene regulatory network analysis can provide greater 
insight into function than simply identifying genes with greatest and/or most significantly changed expression. This is 
because small changes in the expression of genes at nodal positions in networks can have greater systemic effects 
on cell biology than large changes in the expression of non-nodal genes. One example of this is the TUBB gene that 
shows the most statistically significant and greatest fold change in expression of any gene in our analysis but that is 
not very enlightening in terms of understanding the functional consequences of PS1IV loss. (Interestingly, however, 
problems with tubulin polymerization into microtubules have been observed in AD brains [116] and, of course, AD 
pathology is associated with abnormal aggregation of MICROTUBULE-ASSOCIATED PROTEIN TAU, MAPT into 
neurofibrillary tangles. In contrast, it was significant to see that PS1IV is required to maintain or increase the 
expression of the nodal gene CALR under hypoxia since the CALR protein acts as a chaperone in the maturation of 
glycoproteins including APP [117] and has also been observed to be down-regulated in neurons in AD brains [118]. 
This supports that expression of PS2V in AD brain is an attempt by neural cells to cope with the stresses that are 
driving the development of AD pathology. CALR protein is known to exist in complexes with the protein PGRN 
implicated in frontotemporal dementia (FTD) and has also been shown to bind the ATP2A1 protein that binds PSEN1 
[119]. This supports a putative functional link between the major genetic locus mutated in familial AD (PSEN1) and 
the second most commonly mutated gene in familial FTD (PGRN). Interestingly, there are mutations in PSEN1 that 
are thought to cause FTD rather than FAD and these have been observed to differ in their effects on subcellular 
calcium transport [120, 121]. This emphasizes the importance of Ca2+ in PRESENILIN function. Since the 
PRESENILINs and ATP2A1 are all MAM-resident proteins, the data above imply that PGRN will also show 
localization in the MAM. Of course, since PGRN possesses a very high number of disulphide bonds [122], the 





CALR, a protein important for quality control of protein folding and for signal transduction [122], showed that our 
microarray and network analyses are consistent with the known roles of PS1IV and PS2V in modulation of the UPR. 
 
Other observations from our network analysis further support that the human equivalent of PS1IV, PS2V, plays a role 
in AD pathology. Somewhat unexpectedly, we saw that PS1IV is important for the upregulation of 1L1B and CCR5 
that, in humans, have been strongly implicated in the inflammation characterising AD brains. The hypoxia that 
upregulates PS1IV can also drive inflammatory, innate immune responses (e.g. [123]), possibly by increasing the 
amount of incorrectly folded proteins in a cell [124]. In our recent paper describing PS1IV we argued that such 
truncated PSEN isoforms function to inhibit the over-activation of the UPR under hypoxia that can lead to cell death  
[14]. By inhibiting the UPR, PS1IV may permit higher levels of mis-folded proteins under hypoxia and thus stimulate 
inflammatory responses including IL1B expression. We note also that the NLRP3 inflammasome that can promote 
cleavage of pro-IL1β to form active IL1 protein is apparently localised to the MAM [125]. Recently, activation of the 
innate immune response was shown to be suppressed in the brains of mice lacking expression of the fAD gene 
APP [126]. In terms of AD, the APP protein is the most important substrate for the -secretase activity of the 
PSEN proteins and both PS2V and PS1IV can act to increase -secretase activity in cells. Thus, another molecular 
subnetwork connecting PS2V/PS1IV to increased IL1B expression in sAD may be via the A and/or AICD production 
from APP that would increase with increased -secretase activity. 
 
Upregulation of PS2V mRNA expression [8, 11] and accumulation of PS2V protein [127] in the human brain are 
markers of sAD. Since hypoxia is important for induction of PS2V via oxidative stress, this supports that insufficient 
brain oxygenation may be a fundamental driver of sAD pathology. This is consistent with evidence that serum 
markers of hypoxia can distinguish people who progress from mild cognitive impairment (MCI) to AD versus from 
those who do not [128]. Also, hypoxia has been seen to upregulate production of the AD-associated peptide A in 
cultured human neuroblastoma cells and to greatly raise A in serum [129]. Thus, in humans, PS2V may form a 





PS2V action in AD brains might inhibit some of these pathological processes such as the inflammation provoked by 
IL1B expression. It might relieve suppression of the UPR that normally acts to restrict generation of inappropriately 
folded, aggregation-prone proteins. On the other hand, PS2V suppression might increase the cell death that results 
from over-stimulation of the UPR [14] while decreasing expression of CALR with negative consequences for protein 
folding (see above) . Understanding the multifaceted actions in sAD of the human PS2V isoform will require using the 
data we have obtained from zebrafish to generate hypotheses that can be tested in human cellular systems such as 
in neurons derived from induced pluripotent stem cells (iPSCs)[130] . 
 
Our analyses in this paper show that extending examination of the consequences of gene/isoform dysregulation from 
simplistic observation of statistically significant changes in gene expression to construction of statistically significant 
theoretical gene interaction networks enhances our understanding of the normal functions of dysregulated genes and 
protein isoforms. Thus, gene network analysis can contribute greatly to our understanding of the pathological 
mechanisms underlying complex disorders such as AD. The fact that, despite publication of over 80,000 scientific 
papers on AD (excluding reviews), there is no firm consensus on either its underpinning molecular mechanisms or 
disease treatment reinforces the need to implement more advanced analytical strategies such as machine learning 
(data mining), network analysis, promoter architecture analysis, promoter-binding based network analysis, and gene 






This work was supported by the Judith Jane Mason & Harold Stannett Williams Memorial Foundation [grant 13033 to 
ML]; and by the Australian National Health and Medical Research Council [NHMRC, Project Grant APP1061006 to 
ML, MN and EE, http://www.nhmrc.gov.au/] (awarded to A/Professor Michael Lardelli, Dr.Morgan Newman, and Dr. 
Esmaeil Ebrahimie); the School of Molecular and Biomedical Science of the University of Adelaide [support of ML 
and MN]. We are grateful for the support to MN given by the family of Lindsay Carthew. We would like to greatly 
thank Professor Greg Goodall, Centre for Cancer Biology, Adelaide, Australia for his help in microRNA expression 
analysis. We are also thankful for the assistance of Dr. Manijeh Mohammadi Dehcheshmeh, School of Agriculture, 
Food and Wine of The University of Adelaide, Australia in preparation of figures and graphics. 
 
Conflict of Interest Statement 







[1] Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403. 
[2] Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of 
amyloid beta-protein. J. Alzheimers Dis. 3, 75-80. 
[3] Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S, Harabuchi Y (2004) 
Expressions of Matrix Metalloproteinases in Early-Stage Oral Squamous Cell Carcinoma as 
Predictive Indicators for Tumor Metastases and Prognosis. Clin. Cancer Res. 10, 634-640. 
[4] van der Kant R, Goldstein LS (2015) Cellular functions of the amyloid precursor protein from 
development to dementia. Dev Cell 32, 502-515. 
[5] Barage SH, Sonawane KD (2015) Amyloid cascade hypothesis: Pathogenesis and therapeutic 
strategies in Alzheimer's disease. Neuropeptides 52, 1-18. 
[6] Chouraki V, Seshadri S (2014) Genetics of Alzheimer's disease. Adv Genet 87, 245-294. 
[7] Stiller I, Lizak B, Banhegyi G (2014) Physiological functions of presenilins; beyond gamma-
secretase. Curr Pharm Biotechnol 15, 1019-1025. 
[8] Sato N, Hori O, Yamaguchi A, Lambert JC, Chartier-Harlin MC, Robinson PA, Delacourte A, 
Schmidt AM, Furuyama T, Imaizumi K, Tohyama M, Takagi T (1999) A novel presenilin-2 splice 
variant in human Alzheimer's disease brain tissue. J. Neurochem. 72, 2498-2505. 
[9] Sato N, Imaizumi K, Manabe T, Taniguchi M, Hitomi J, Katayama T, Yoneda T, Morihara T, Yasuda 
Y, Takagi T, Kudo T, Tsuda T, Itoyama Y, Makifuchi T, Fraser PE, St George-Hyslop P, Tohyama M 
(2001) Increased production of beta-amyloid and vulnerability to endoplasmic reticulum stress 
by an aberrant spliced form of presenilin 2. J. Biol. Chem. 276, 2108-2114. 
[10] Nishikawa A, Manabe T, Katayama T, Kudo T, Matsuzaki S, Yanagita T, Okuda H, Bando Y, 
Tohyama M (2004) Novel function of PS2V: change in conformation of tau proteins. Biochem. 
Biophys. Res. Commun. 318, 435-438. 
[11] Smith MJ, Sharples RA, Evin G, McLean CA, Dean B, Pavey G, Fantino E, Cotton RGH, Imaizumi K, 
Masters CL, Cappai R, Culvenor JG (2004) Expression of truncated presenilin 2 splice variant in 
Alzheimer's disease, bipolar disorder, and schizophrenia brain cortex. Mol. Brain Res. 127, 128-
135. 
[12] Newman M, Wilson L, Verdile G, Lim A, Khan I, Moussavi Nik SH, Pursglove S, Chapman G, 
Martins RN, Lardelli M (2014) Differential, dominant activation and inhibition of Notch signalling 
and APP cleavage by truncations of PSEN1 in human disease. Hum. Mol. Genet. 23, 602-617. 
[13] Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu CE, Bird TD (2010) Alzheimer's disease 
phenotypes and genotypes associated with mutations in presenilin 2. Brain 133, 1143-1154. 
[14] Moussavi Nik SH, Newman M, Wilson L, Ebrahimie E, Wells S, Musgrave I, Verdile G, Martins RN, 
Lardelli M (2015) Alzheimer's disease-related peptide PS2V plays ancient, conserved roles in 
suppression of the unfolded protein response under hypoxia and stimulation of γ-secretase 
activity. Hum. Mol. Genet. 24, 3662-3678. 
[15] Sharman MJ, Moussavi Nik SH, Chen MM, Ong D, Wijaya L, Laws SM, Taddei K, Newman M, 
Lardelli M, Martins RN, Verdile G (2013) The Guinea Pig as a Model for Sporadic Alzheimer's 
Disease (AD): The Impact of Cholesterol Intake on Expression of AD-Related Genes. PLoS One 8, 
e66235. 
[16] Westerfield M (2007) The zebrafish book. A guide for the laboratory use of zebrafish (Danio 





[17] Nornes S, Newman M, Verdile G, Wells S, Stoick-Cooper CL, Tucker B, Frederich-Sleptsova I, 
Martins R, Lardelli M (2008) Interference with splicing of Presenilin transcripts has potent 
dominant negative effects on Presenilin activity. Hum Mol Genet 17, 402-412. 
[18] Gao F, Okunieff P, Han Z, Ding I, Wang L, Liu W, Zhang J, Yang S, Chen J, Underhill C, Kim S, Zhang 
L (2005) Hypoxia-Induced Alterations in Hyaluronan and Hyaluronidase In Oxygen Transport to 
Tissue XXVI, Okunieff P, Williams J, Chen Y, eds. Springer US, pp. 249-256. 
[19] Nik SHM, Newman M, Ganesan S, Chen M, Martins R, Verdile G, Lardelli M (2014) Hypoxia alters 
expression of Zebrafish Microtubule-associated protein Tau (mapta, maptb) gene transcripts. 
BMC research notes 7, 767. 
[20] Moussavi Nik SH, Newman M, Lardelli M (2011) The response of HMGA1 to changes in oxygen 
availability is evolutionarily conserved. Exp. Cell Res. 317, 1503-1512. 
[21] Moussavi Nik SH, Wilson L, Newman M, Croft K, Mori TA, Musgrave I, Lardelli M (2012) The 
BACE1-PSEN-AbetaPP regulatory axis has an ancient role in response to low oxygen/oxidative 
stress. J Alzheimers Dis 28, 515-530. 
[22] Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for 
high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193. 
[23] Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP (2003) Summaries of Affymetrix 
GeneChip probe level data. Nucleic Acids Res 31, e15. 
[24] Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003) 
Exploration, normalization, and summaries of high density oligonucleotide array probe level 
data. Biostatistics 4, 249-264. 
[25] Fruzangohar M, Ebrahimie E, Ogunniyi AD, Mahdi LK, Paton JC, Adelson DL (2013) Comparative 
GO: A Web Application for Comparative Gene Ontology and Gene Ontology-Based Gene 
Selection in Bacteria. PLoS One 8, e58759. 
[26] Fruzangohar M, Ebrahimie E, Adelson DL (2014) Application of Global Transcriptome Data in 
Gene Ontology Classification and Construction of a Gene Ontology Interaction Network. bioRxiv, 
doi: http://dx.doi.org/10.1101/004911. 
[27] Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, 
Pomeroy SL, Golub TR, Lander ES (2005) Gene set enrichment analysis: a knowledge-based 
approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102, 
15545-15550. 
[28] Nikitin A, Egorov S, Daraselia N, Mazo I (2003) Pathway studio—the analysis and navigation of 
molecular networks. Bioinformatics 19, 2155-2157. 
[29] Novichkova S, Egorov S, Daraselia N (2003) MedScan, a natural language processing engine for 
MEDLINE abstracts. Bioinformatics 19, 1699-1706. 
[30] Hosseinpour B, HajiHoseini V, Kashfi R, Ebrahimie E, Hemmatzadeh F (2012) Protein interaction 
network of Arabidopsis thaliana female gametophyte development identifies novel proteins and 
relations. PLoS One 7, e49931. 
[31] Alanazi I, Ebrahimie E, Hoffmann P, Adelson DL (2013) Combined gene expression and 
proteomic analysis of EGF induced apoptosis in A431 cells suggests multiple pathways trigger 
apoptosis. Apoptosis 18, 1291-1305. 
[32] Ebrahimie M, Esmaeili F, Cheraghi S, Houshmand F, Shabani L, Ebrahimie E (2014) Efficient and 
Simple Production of Insulin-Producing Cells from Embryonal Carcinoma Stem Cells Using Mouse 
Neonate Pancreas Extract, As a Natural Inducer. PLoS One 9, e90885. 
[33] Alisoltani A, Fallahi H, Ebrahimi M, Ebrahimi M, Ebrahimie E (2014) Prediction of Potential 






[34] Lin C-Y, Chin C-H, Wu H-H, Chen S-H, Ho C-W, Ko M-T (2008) Hubba: hub objects analyzer—a 
framework of interactome hubs identification for network biology. Nucleic Acids Res. 36, W438-
W443. 
[35] Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T 
(2003) Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction 
Networks. Genome Res. 13, 2498-2504. 
[36] Khosravi P, Gazestani VH, Asgari Y, Law B, Sadeghi M, Goliaei B (2014) Network-based approach 
reveals Y chromosome influences prostate cancer susceptibility. Comput. Biol. Med. 54, 24-31. 
[37] Newman M, Lardelli M, Ebrahimie E (2014) Using the Zebrafish model for Alzheimer’s Disease 
Research. Frontiers in Genetics 5, 189. 
[38] Mansouri A, Esmaeili F, Nejatpour A, Houshmand F, Shabani L, Ebrahimie E (2014) 
Differentiation of P19 embryonal carcinoma stem cells into insulin-producing cells promoted by 
pancreas-conditioned medium. J. Tissue Eng. Regen. Med. In press, doi: 10.1002/term.1927. 
[39] Cook JL, Re RN, deHaro DL, Abadie JM, Peters M, Alam J (2008) The Trafficking Protein GABARAP 
Binds to and Enhances Plasma Membrane Expression and Function of the Angiotensin II Type 1 
Receptor. Circ.Res. 102, 1539-1547. 
[40] Tanji K, Mori F, Kakita A, Takahashi H, Wakabayashi K (2011) Alteration of autophagosomal 
proteins (LC3, GABARAP and GATE-16) in Lewy body disease. Neurobiol. Dis. 43, 690-697. 
[41] Nowak J, Archange C, Tardivel-Lacombe J, Pontarotti P, Pébusque M-J, Vaccaro MI, Velasco G, 
Dagorn J-C, Iovanna JL (2009) The TP53INP2 Protein Is Required for Autophagy in Mammalian 
Cells. Mol. Biol. Cell 20, 870-881. 
[42] Hemelaar J, Lelyveld VS, Kessler BM, Ploegh HL (2003) A Single Protease, Apg4B, Is Specific for 
the Autophagy-related Ubiquitin-like Proteins GATE-16, MAP1-LC3, GABARAP, and Apg8L. J. Biol. 
Chem. 278, 51841-51850. 
[43] Weidberg H, Shvets E, Shpilka T, Shimron F, Shinder V, Elazar Z (2010) LC3 and GATE-
16/GABARAP subfamilies are both essential yet act differently in autophagosome biogenesis. 
EMBO J. 29, 1792-1802. 
[44] Mizushima N, Ohsumi Y, Yoshimori T (2002) Autophagosome formation in mammalian cells. Cell 
Struct. Funct. 27, 421-429. 
[45] Yoshimori T (2004) Autophagy: a regulated bulk degradation process inside cells. Biochem. 
Biophys. Res. Commun. 313, 453-458. 
[46] Maturana AD, Wälchli S, Iwata M, Ryser S, Van Lint J, Hoshijima M, Schlegel W, Ikeda Y, 
Tanizawa K, Kuroda Si (2008) Enigma homolog 1 scaffolds protein kinase D1 to regulate the 
activity of the cardiac L-type voltage-gated calcium channel. Cardiovasc. Res. 78, 458-465. 
[47] De Mello WC (2011) Novel aspects of angiotensin II action in the heart. Implications to 
myocardial ischemia and heart failure. Regul. Pept. 166, 9-14. 
[48] Kato T, Iwayama Y, Kakiuchi C, Iwamoto K, Yamada K, Minabe Y, Nakamura K, Mori N, Fujii K, 
Nanko S, Yoshikawa T (2005) Gene expression and association analyses of LIM (PDLIM5) in 
bipolar disorder and schizophrenia. Mol. Psychiatry 10, 1045-1055. 
[49] Iga J-i, Ueno S-i, Yamauchi K, Numata S, Motoki I, Tayoshi S, Kinouchi S, Ohta K, Song H, Morita 
K, Rokutan K, Tanabe H, Sano A, Ohmori T (2006) Gene expression and association analysis of 
LIM (PDLIM5) in major depression. Neurosci. Lett. 400, 203-207. 
[50] Li A, Ponten F, dos Remedios CG (2012) The interactome of LIM domain proteins: The 
contributions of LIM domain proteins to heart failure and heart development. Proteomics 12, 
203-225. 
[51] Swindell EC, Zilinski CA, Hashimoto R, Shah R, Lane ME, Jamrich M (2008) Regulation and 





[52] Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U, 
Bondesson M (2005) Hypoxia requires notch signaling to maintain the undifferentiated cell 
state. Dev. Cell 9, 617-628. 
[53] Keith B, Simon MC (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell 129, 465-472. 
[54] Ethell DW (2010) An amyloid-notch hypothesis for Alzheimer's disease. Neuroscientist 16, 614-
617. 
[55] Bai T, Seebald JL, Kim KE, Ding HM, Szeto DP, Chang HC (2010) Disruption of zebrafish cyclin G-
associated kinase (GAK) function impairs the expression of Notch-dependent genes during 
neurogenesis and causes defects in neuronal development. BMC Dev. Biol. 10, 7. 
[56] Rhodes SL, Sinsheimer JS, Bordelon Y, Bronstein JM, Ritz B (2011) Replication of GWAS 
associations for GAK and MAPT in Parkinson's disease. Ann. Hum. Genet. 75, 195-200. 
[57] Dumitriu A, Pacheco CD, Wilk JB, Strathearn KE, Latourelle JC, Goldwurm S, Pezzoli G, Rochet JC, 
Lindquist S, Myers RH (2011) Cyclin-G-associated kinase modifies alpha-synuclein expression 
levels and toxicity in Parkinson's disease: results from the GenePD Study. Hum. Mol. Genet. 20, 
1478-1487. 
[58] Newman M, Tucker B, Nornes S, Ward A, Lardelli M (2009) Altering presenilin gene activity in 
zebrafish embryos causes changes in expression of genes with potential involvement in 
Alzheimer's disease pathogenesis. J Alzheimers Dis. 16, 133-147. 
[59] Moussavi Nik SH, Wilson L, Newman M, Croft K, Mori TA, Musgrave I, Lardelli M (2012) The 
BACE1-PSEN-AβPP Regulatory Axis has an Ancient Role in Response to Low Oxygen/Oxidative 
Stress. J. Alzheimers Dis. 28, 515-530. 
[60] Herr D, Rodewald M, Fraser HM, Hack G, Konrad R, Kreienberg R, Wulff C (2008) Regulation of 
endothelial proliferation by the renin-angiotensin system in human umbilical vein endothelial 
cells. Reproduction 136, 125-130. 
[61] Quillien A, Moore JC, Shin M, Siekmann AF, Smith T, Pan L, Moens CB, Parsons MJ, Lawson ND 
(2014) Distinct Notch signaling outputs pattern the developing arterial system. Development 
141, 1544-1552. 
[62] Ricchiuti V, Lian CG, Oestreicher EM, Tran L, Stone JR, Yao T, Seely EW, Williams GH, Adler GK 
(2009) Estradiol increases angiotensin II type 1 receptor in hearts of ovariectomized rats. J 
Endocrinol 200, 75-84. 
[63] Zouali M, Sarmay G (2004) B lymphocyte signaling pathways in systemic autoimmunity: 
Implications for pathogenesis and treatment. Arthritis Rheum. 50, 2730-2741. 
[64] Guo D, Zhang H, Liu L, Wang L, Cheng Y, Qiao Z (2004) Testosterone influenced the expression of 
Notch1, Notch2 and Jagged1 induced by lipopolysaccharide in macrophages. Exp. Toxicol. 
Pathol. 56, 173-179. 
[65] Matsuda N, Hattori Y, Sakuraya F, Kobayashi M, Zhang X-H, Kemmotsu O, Gando S (2002) 
Hemodynamic significance of histamine synthesis and histamine H1- and H2-receptor gene 
expression during endotoxemia. Naunyn-Schmiedebergs Arch. Pharmacol. 366, 513-521. 
[66] Wang X, Rousset CI, Hagberg H, Mallard C (2006) Lipopolysaccharide-induced inflammation and 
perinatal brain injury. Seminars in Fetal and Neonatal Medicine 11, 343-353. 
[67] Ackermann J, Ashton G, Lyons S, James D, Hornung JP, Jones N, Breitwieser W (2011) Loss of 
ATF2 function leads to cranial motoneuron degeneration during embryonic mouse 
development. PLoS One 6, e19090. 
[68] Van Dam H, Wilhelm D, Herr I, Steffen A, Herrlich P, Angel P (1995) ATF-2 is preferentially 
activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic 





[69] Bhunia AK, Piontek K, Boletta A, Liu L, Qian F, Xu PN, Germino FJ, Germino GG (2002) PKD1 
induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling 
pathway in a process requiring PKD2. Cell 109, 157-168. 
[70] Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, Guardia-Laguarta C, de Groof AJ, 
Madra M, Ikenouchi J, Umeda M, Bird TD, Sturley SL, Schon EA (2012) Upregulated function of 
mitochondria-associated ER membranes in Alzheimer disease. EMBO J 31, 4106-4123. 
[71] Simmen T, Lynes EM, Gesson K, Thomas G (2010) Oxidative protein folding in the endoplasmic 
reticulum: tight links to the mitochondria-associated membrane (MAM). Biochim. Biophys. Acta 
1798, 1465-1473. 
[72] Mattson MP, LaFerla FM, Chan SL, Leissring MA, Shepel PN, Geiger JD (2000) Calcium signaling in 
the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends in Neurosciences 
23, 222-229. 
[73] Clapham DE (2007) Calcium Signaling. Cell 131, 1047-1058. 
[74] Timmins JM, Ozcan L, Seimon TA, Li G, Malagelada C, Backs J, Backs T, Bassel-Duby R, Olson EN, 
Anderson ME, Tabas I (2009) Calcium/calmodulin-dependent protein kinase II links ER stress 
with Fas and mitochondrial apoptosis pathways. J. Clin. Invest. 119, 2925-2941. 
[75] Whyte L, Huang Y-Y, Torres K, Mehta RG (2007) Molecular mechanisms of resveratrol action in 
lung cancer cells using dual protein and microarray analyses. Cancer Res. 67, 12007-12017. 
[76] O'DRISCOLL L, KENNY E, MEHTA JP, DOOLAN P, JOYCE H, GAMMELL P, HILL A, O'DALY B, 
O'GORMAN D, CLYNES M (2008) Feasibility and relevance of global expression profiling of gene 
transcripts in serum from breast cancer patients using whole genome microarrays and 
quantitative RT-PCR. Cancer Genomics Proteomics 5, 95-104. 
[77] Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D (1998) GeneCards: a novel functional genomics 
compendium with automated data mining and query reformulation support. Bioinformatics 14, 
656-664. 
[78] Safran M, Solomon I, Shmueli O, Lapidot M, Shen-Orr S, Adato A, Ben-Dor U, Esterman N, Rosen 
N, Peter I (2002) GeneCards™ 2002: towards a complete, object-oriented, human gene 
compendium. Bioinformatics 18, 1542-1543. 
[79] Yang Q, She H, Gearing M, Colla E, Lee M, Shacka JJ, Mao Z (2009) Regulation of neuronal 
survival factor MEF2D by chaperone-mediated autophagy. Science 323, 124-127. 
[80] Youn HD, Chatila TA, Liu JO (2000) Integration of calcineurin and MEF2 signals by the coactivator 
p300 during T-cell apoptosis. EMBO J 19, 4323-4331. 
[81] Škuljec J, Sun H, Pul R, Bénardais K, Ragancokova D, Moharregh-Khiabani D, Kotsiari A, Trebst C, 
Stangel M (2011) CCL5 induces a pro-inflammatory profile in microglia< i> in vitro</i>. Cell. 
Immunol. 270, 164-171. 
[82] Reale M, Iarlori C, Feliciani C, Gambi D (2008) Peripheral chemokine receptors, their ligands, 
cytokines and Alzheimer's disease. J. Alzheimers Dis. 14, 147-159. 
[83] Goldeck D, Larbi A, Pellicanó M, Alam I, Zerr I, Schmidt C, Fulop T, Pawelec G (2013) Enhanced 
Chemokine Receptor Expression on Leukocytes of Patients with Alzheimer's Disease. PLoS One 8, 
e66664. 
[84] Cowell RM, Xu H, Parent JM, Silverstein FS (2006) Microglial expression of chemokine receptor 
CCR5 during rat forebrain development and after perinatal hypoxia–ischemia. J. Neuroimmunol. 
173, 155-165. 
[85] Bosco MC, Reffo G, Puppo M, Varesio L (2004) Hypoxia inhibits the expression of the CCR5 
chemokine receptor in macrophages. Cell. Immunol. 228, 1-7. 
[86] Gozal D, Sachleben LR, Czyzyk-Krzeska MF, Li RC, Guo S-Z, Gozal E, Shah ZA, Pequignot J-M, 
Pequignot J (2011) Tyrosine hydroxylase expression and activity in the rat. Am. J. Physiol. Cell 





[87] Nakashima A, Ota A, Kaneko YS, Mori K, Nagasaki H, Nagatsu T (2013) A possible 
pathophysiological role of tyrosine hydroxylase in Parkinson’s disease suggested by postmortem 
brain biochemistry: a contribution for the special 70th birthday symposium in honor of Prof. 
Peter Riederer. J. Neural Transm. 120, 49-54. 
[88] Zhang D, Kanthasamy A, Anantharam V, Kanthasamy A (2011) Effects of manganese on tyrosine 
hydroxylase (TH) activity and TH-phosphorylation in a dopaminergic neural cell line. Toxicol. 
Appl. Pharmacol. 254, 65-71. 
[89] Gehrke S, Imai Y, Sokol N, Lu B (2010) Pathogenic LRRK2 negatively regulates microRNA-
mediated translational repression. Nature 466, 637-641. 
[90] Sciacca F, Ferri C, Licastro F, Veglia F, Biunno I, Gavazzi A, Calabrese E, Martinelli Boneschi F, 
Sorbi S, Mariani C (2003) Interleukin-1B polymorphism is associated with age at onset of 
Alzheimer’s disease. Neurobiol. Aging 24, 927-931. 
[91] Louboutin J-P, S Strayer D (2013) Relationship Between the Chemokine Receptor CCR5 and 
Microglia in Neurological Disorders: Consequences of Targeting CCR5 on Neuroinflammation, 
Neuronal Death and Regeneration in a Model of Epilepsy. CNS Neurol. Disord.-Drug Targets 12, 
815-829. 
[92] Maier J, Kincaid C, Pagenstecher A, Campbell IL (2002) Regulation of signal transducer and 
activator of transcription and suppressor of cytokine-signaling gene expression in the brain of 
mice with astrocyte-targeted production of interleukin-12 or experimental autoimmune 
encephalomyelitis. Am. J. Pathol. 160, 271-288. 
[93] Burns K, Duggan B, Atkinson EA, Famulski KS, Nemer M, Bleackley RC, Michalak M (1994) 
Modulation of gene expression by calreticulin binding to the glucocorticoid receptor. Nature 
367, 476-480. 
[94] Almeida S, Zhou L, Gao F-B (2011) Progranulin, a glycoprotein deficient in frontotemporal 
dementia, is a novel substrate of several protein disulfide isomerase family proteins. PLoS One 6, 
e26454. 
[95] Area-Gomez E, de Groof AJ, Boldogh I, Bird TD, Gibson GE, Koehler CM, Yu WH, Duff KE, Yaffe 
MP, Pon LA (2009) Presenilins are enriched in endoplasmic reticulum membranes associated 
with mitochondria. Am. J. Pathol. 175, 1810-1816. 
[96] Medina PP, Carretero J, Ballestar E, Angulo B, Lopez-Rios F, Esteller M, Sanchez-Cespedes M 
(2005) Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung 
cancer cells. Hum. Mol. Genet. 14, 973-982. 
[97] Kong W, Mou X, Liu Q, Chen Z, Vanderburg CR, Rogers JT, Huang X (2009) Independent 
component analysis of Alzheimer's DNA microarray gene expression data. Mol. Neurodegener. 4, 
1-14. 
[98] Dityatev A, Schachner M, Sonderegger P (2010) The dual role of the extracellular matrix in 
synaptic plasticity and homeostasis. Nat. Rev. Neurosci. 11, 735-746. 
[99] Antoniu SA (2012) Discontinued drugs 2011: pulmonary, allergy, gastrointestinal and arthritis. 
Expert Opin. Investig. Drugs 21, 1607-1618. 
[100] Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R, Xie C, Chen J, Deng Q, Yamout M (2007) PRAK 
Is Essential for< i> ras</i>-Induced Senescence and Tumor Suppression. Cell 128, 295-308. 
[101] McDonald DR, Bamberger ME, Combs CK, Landreth GE (1998) β-Amyloid fibrils activate parallel 
mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J. Neurosci. 18, 
4451-4460. 
[102] Vasco VRL, Cardinale G, Polonia P (2012) Deletion of PLCB1 gene in schizophrenia‐affected 





[103] Prabakaran S, Swatton J, Ryan M, Huffaker S, Huang J-J, Griffin J, Wayland M, Freeman T, 
Dudbridge F, Lilley K (2004) Mitochondrial dysfunction in schizophrenia: evidence for 
compromised brain metabolism and oxidative stress. Mol. Psychiatry 9, 684-697. 
[104] Katayama T, Imaizumi K, Sato N, Miyoshi K, Kudo T, Hitomi J, Morihara T, Yoneda T, Gomi F, 
Mori Y (1999) Presenilin-1 mutations downregulate the signalling pathway of the unfolded-
protein response. Nat. Cell Biol. 1, 479-485. 
[105] Zhang X, Szabo E, Michalak M, Opas M (2007) Endoplasmic reticulum stress during the 
embryonic development of the central nervous system in the mouse. Int. J. Dev. Neurosci. 25, 
455-463. 
[106] Molinari M, Helenius A (1999) Glycoproteins form mixed disulphides with oxidoreductases 
during folding in living cells. Nature 402, 90-93. 
[107] Jin H, Sanjo N, Uchihara T, Watabe K, George-Hyslop PS, Fraser PE, Mizusawa H (2010) 
Presenilin-1 holoprotein is an interacting partner of sarco endoplasmic reticulum calcium-
ATPase and confers resistance to endoplasmic reticulum stress. J. Alzheimers Dis. 20, 261-273. 
[108] Roussel BD, Kruppa AJ, Miranda E, Crowther DC, Lomas DA, Marciniak SJ (2013) Endoplasmic 
reticulum dysfunction in neurological disease. Lancet Neurol. 12, 105-118. 
[109] Lee J-H, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, 
Massey AC, Sovak G (2010) Lysosomal proteolysis and autophagy require presenilin 1 and are 
disrupted by Alzheimer-related PS1 mutations. Cell 141, 1146-1158. 
[110] Brodsky JL (2012) Cleaning up: ER-associated degradation to the rescue. Cell 151, 1163-1167. 
[111] Schon EA, Area-Gomez E (2010) Is Alzheimer's disease a disorder of mitochondria-associated 
membranes? J. Alzheimers Dis. 20, 281-292. 
[112] Petushkova NA, Kuznetsova GP, Larina OV, Kisrieva YS, Samenkova NF, Trifonova OP, 
Miroshnichenko YV, Zolotarev KV, Karuzina, II, Ipatova OM, Lisitsa AV (2015) One-dimensional 
proteomic profiling of Danio rerio embryo vitellogenin to estimate quantum dot toxicity. 
Proteome Sci 13, 17. 
[113] W Friedrich F, Carrier L (2012) Genetics of hypertrophic and dilated cardiomyopathy. Curr. 
Pharm.  biotech. 13, 2467-2476. 
[114] Nik SHM, Newman M, Wilson L, Ebrahimie E, Wells S, Musgrave I, Verdile G, Martins RN, Lardelli 
M (2015) Alzheimer's disease-related peptide PS2V plays ancient, conserved roles in suppression 
of the unfolded protein response under hypoxia and stimulation of γ-secretase activity. Hum. 
Mol. Genet., ddv110. 
[115] Bales KR (2012) The value and limitations of transgenic mouse models used in drug discovery for 
Alzheimer's disease: an update. Expert Opin Drug Discov 7, 281-297. 
[116] Boutté AM, Neely MD, Bird TD, Montine KS, Montine TJ (2005) Diminished taxol/GTP-stimulated 
tubulin polymerization in diseased region of brain from patients with late-onset or inherited 
Alzheimer's disease or frontotemporal dementia with parkinsonism linked to chromosome-17 
but not individuals with mild cogni. J. Alzheimers Dis. 8, 1-6. 
[117] Johnson RJ, Xiao G, Shanmugaratnam J, Fine RE (2001) Calreticulin functions as a molecular 
chaperone for the β-amyloid precursor protein1. Neurobiology of Aging 22, 387-395. 
[118] Lin Q, Cao Y, Gao J (2014) Serum Calreticulin Is a Negative Biomarker in Patients with 
Alzheimer’s Disease. International journal of molecular sciences 15, 21740-21753. 
[119] Ihara Y, Kageyama K, Kondo T (2005) Overexpression of calreticulin sensitizes SERCA2a to 
oxidative stress. Biochem. Biophys. Res. Commun. 329, 1343-1349. 
[120] Nelson O, Tu H, Lei T, Bentahir M, De Strooper B, Bezprozvanny I (2007) Familial Alzheimer 






[121] Cheung K-H, Mei L, Mak D-OD, Hayashi I, Iwatsubo T, Kang DE, Foskett JK (2010) Gain-of-
function enhancement of IP3 receptor modal gating by familial Alzheimer's disease-linked 
presenilin mutants in human cells and mouse neurons. Sci. Signal. 3, ra22. 
[122] Prell T, Lautenschläger J, Grosskreutz J (2013) Calcium-dependent protein folding in amyotrophic 
lateral sclerosis. Cell calcium 54, 132-143. 
[123] Yang Z, Zhong L, Zhong S, Xian R, Yuan B (2015) Hypoxia induces microglia autophagy and neural 
inflammation injury in focal cerebral ischemia model. Exp. Mol. Pathol. 98, 219-224. 
[124] Shenderov K, Riteau N, Yip R, Mayer-Barber KD, Oland S, Hieny S, Fitzgerald P, Oberst A, Dillon 
CP, Green DR, Cerundolo V, Sher A (2014) Cutting Edge: Endoplasmic Reticulum Stress Licenses 
Macrophages To Produce Mature IL-1β in Response to TLR4 Stimulation through a Caspase-8– 
and TRIF-Dependent Pathway. J. Immunol. 192, 2029-2033. 
[125] Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, Akira S (2013) Microtubule-driven 
spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat. 
Immunol. 14, 454-460. 
[126] Carrano A, Das P (2015) Altered Innate Immune and Glial Cell Responses to Inflammatory Stimuli 
in Amyloid Precursor Protein Knockout Mice. PLoS One 10, e0140210. 
[127] Manabe T, Katayama T, Sato N, Kudo T, Matsuzaki S, Imaizumi K, Tohyama M (2002) The 
cytosolic inclusion bodies that consist of splice variants that lack exon 5 of the presenilin-2 gene 
differ obviously from Hirano bodies observed in the brain from sporadic cases of Alzheimer's 
disease patients. Neuroscience Letters 328, 198-200. 
[128] Orešič M, Hyötyläinen T, Herukka S, Sysi-Aho M, Mattila I, Seppänan-Laakso T, Julkunen V, 
Gopalacharyulu P, Hallikainen M, Koikkalainen J (2011) Metabolome in progression to 
Alzheimer's disease. Transl. Psychiatr 1, e57. 
[129] Zeng H, Chen Q, Zhao B (2004) Genistein ameliorates β-amyloid peptide (25–35)-induced 
hippocampal neuronal apoptosis. Free Radic. Biol. Med. 36, 180-188. 
[130] Liu Q, Waltz S, Woodruff G, Ouyang J, Israel MA, Herrera C, Sarsoza F, Tanzi RE, Koo EH, Ringman 
JM, Goldstein LS, Wagner SL, Yuan SH (2014) Effect of potent gamma-secretase modulator in 
human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant 
carriers. JAMA Neurol 71, 1481-1489. 
[131] Mestizo Gutiérrez SL, Herrera Rivero M, Cruz Ramírez N, Hernández E, Aranda-Abreu GE (2014) 
Decision trees for the analysis of genes involved in Alzheimer׳s disease pathology. J. Theor. Biol. 
357, 21-25. 
[132] AL-Dlaeen D, Alashqur A (2014) in Computer Science and Information Technology (CSIT), 2014 
6th International Conference on IEEE, pp. 122-126. 
[133] Bakhtiarizadeh M, Moradi-Shahrbabak M, Ebrahimie E (2014) Transcriptional regulatory 
network analysis of the over-expressed genes in adipose tissue. Genes Genom. 36, 105-117. 
[134] Hosseinpour B, Bakhtiarizadeh MR, Khosravi P, Ebrahimie E (2013) Predicting distinct 
organization of transcription factor binding sites on the promoter regions: a new genome-based 





Table 1 A. The most significantly over-expressed genes after blockage of PS1IV formation during mimicry of hypoxia.  The complete list is presented 
at Supplementary 2. It should be noted that these genes are normally repressed by the formation of PS1IV. 
 
Gene name Affymetrix 
transcript  ID 
Fold 
change 
P-value Regulation Description 
ACY1 13124285 1.43802 0.003253 UP aminoacylase 1 
AGTR1 13148727 1.212083 0.032714 UP angiotensin II receptor, type 1 
ANGPTL2 13001248 2.020158 3.07E-07 UP angiopoietin-like 2 
CAMTA1 12976155 2.474301 2.73E-07 UP calmodulin binding transcription activator 1 
CD22 12959348 1.338294 0.019724 UP CD22 molecule 
EBP 13139214 1.367905 0.039918 UP emopamil binding protein (sterol isomerase) 
ECM2 13119638 1.493006 0.000693 UP extracellular matrix protein 2, female organ and adipocyte specific 
FOXE3 13244659 1.310028 0.00264 UP forkhead box E3 
GAK 13201928 1.232148 0.006471 UP cyclin G associated kinase 
HLA-DPB1 13254612 1.670167 0.002895 UP major histocompatibility complex, class II, DP beta 1 
HRH2 13007297 1.716072 9.85E-05 UP histamine receptor H2 
HSPA4 13242974 3.854714 1.09E-11 UP heat shock 70kDa protein 4 
HTR3B 13110168 1.303078 0.00088 UP 5-hydroxytryptamine (serotonin) receptor 3B 





MRC2 13225339 1.228197 0.047657 UP mannose receptor, C type 2 
MSL1 13174217 1.402262 0.018025 UP male-specific lethal 1 homolog (Drosophila) 
MUM1 (IRF4) 13090651 1.666235 0.001652 UP melanoma associated antigen (mutated) 1 (INTERFERON REGULATORY FACTOR 4) 
NOTCH2 13244612 1.4356 0.039308 UP notch 2 
NRN1L 13237032 1.389511 0.050836 UP neuritin 1-like 
OLFM4 13170496 1.39979 0.000831 UP olfactomedin 4 
PIM3 13256027 2.796259 0.000201 UP pim-3oncogene 
PKD1 13145022 1.766053 0.000564 UP polycystic kidney disease 1 (autosomal dominant) 
POLR3G 13198080 1.355577 0.000653 UP polymerase (RNA) III (DNA directed) polypeptide G (32kD) 
PTPRH 13144075 1.579611 0.003511 UP protein tyrosine phosphatase, receptor type, H 
RBM5 13217068 1.644646 0.001741 UP RNA binding motif protein 5 
RICTOR 13192653 1.834237 8.6E-05 UP RPTOR independent companion of MTOR, complex 2 
 
Table 2 B. The most significantly under-expressed genes after blockage of the formation of PS1IV during mimicry of hypoxia.  The complete list is 
presented in Supplemental Data 3. It should be noted that these genes are normally up-regulated by the formation of PS1IV. 
 
Gene name Affymetrix 
transcript  ID 
Fold 
change* 
P-value Regulation Description 





AIDA 13099479 -2.237709 1.0207E-08 DOWN axin interactor, dorsalization associated 
AKAP1B 13021077 -1.537301 0.02472395 DOWN A kinase (PRKA) anchor protein 1b 
AMPD1 13243554 -2.080487 0.0008468 DOWN adenosine monophosphate deaminase 1 
CALR 13125424 -2.135172 0.00020882 DOWN calreticulin 
CETN2 13013035 -1.694809 1.9335E-05 DOWN centrin, EF-hand protein, 2 
CKMT1A 13161691 -2.35532 8.4446E-10 DOWN creatine kinase, mitochondrial 1A 
EEF1B2 13212503 -1.911308 0.02344456 DOWN eukaryotic translation elongation factor 1 beta 2 
GBX2 13212750 -2.016745 1.2832E-06 DOWN gastrulation brain homeobox 2 
GORASP1 13148147 -1.235676 0.0491116 DOWN golgi reassembly stacking protein 1, 65kDa 
GRAMD1B 13065585 -1.134146 0.02169604 DOWN GRAM domain containing 1B 
GZMM 13122283 -1.07633 0.04767155 DOWN granzyme M (lymphocyte met-ase 1) 
HSDL2 12961615 -2.07654 4.9238E-08 DOWN hydroxysteroid dehydrogenase like 2 
HSPA8 12969404 -1.667337 0.01602544 DOWN heat shock 70kDa protein 8 
IL1B 12971431 -2.867022 0.00750858 DOWN interleukin 1, beta 
LSMD1 13208954 -1.911134 2.0139E-08 DOWN LSM domain containing 1 
MAPKAPK5 13210281 -1.601199 7.2304E-06 DOWN mitogen-activated protein kinase-activated protein kinase 5 
MRPS12 13116129 -1.303939 0.00596112 DOWN mitochondrial ribosomal protein S12 
NLRP12 12948631 -1.280818 0.00166266 DOWN NLR family, pyrin domain containing 12 





PLCB1 13106935 -1.357149 0.00755506 DOWN phospholipase C, beta 1 (phosphoinositide-specific) 
PLEKHA4 13147690 -1.13717 0.01677694 DOWN pleckstrin homology domain containing, family A (phosphoinositide binding specific) 
member 4 
POP7 13227367 -1.851494 1.6801E-06 DOWN processing of precursor 7, ribonuclease P/MRP subunit (S. cerevisiae) 
POU4F2 12948390 -2.494429 3.6522E-12 DOWN POU class 4 homeobox 2 
RAB3C 13251770 -1.803195 5.4026E-05 DOWN RAB3C, member RAS oncogene family 
RGS8 13214775 -1.479107 0.00691868 DOWN regulator of G-protein signaling 8 
RPL26 13012615 -1.393831 0.00272945 DOWN ribosomal protein L26 
RPL28 13035086 -1.393911 0.00271368 DOWN ribosomal protein L28 
RPL7A 13196034 -1.576352 1.1759E-05 DOWN ribosomal protein L7a 
Rpl9 12946795 -2.255041 2.09E-06 DOWN ribosomal protein L9 
RPL9 12946795 -2.255041 2.09E-06 DOWN ribosomal protein L9 
RPS15A 13167130 -1.785676 0.04753847 DOWN ribosomal protein S15a 
RPS19 13031783 -1.093388 0.05029653 DOWN ribosomal protein S19 
Rps20 13240815 -1.429581 0.01435088 DOWN ribosomal protein S20 
RRM2 13103533 -1.70361 0.00079271 DOWN ribonucleotide reductase M2 
SGCG 13018621 -1.739535 0.00064507 DOWN sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) 
SHISA7 13073348 -1.505375 0.01521283 DOWN shisa homolog 7 (Xenopus laevis) 





SMARCA4 13205694 -1.442988 0.0126954 DOWN SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, 
member 4 
SRCAP 12985971 -2.4494 6.6558E-07 DOWN Snf2-related CREBBP activator protein 
SSU72 13119040 -1.988331 8.3227E-05 DOWN SSU72 RNA polymerase II CTD phosphatase homolog (S. cerevisiae) 
SYN2 13137535 -2.097409 9.4208E-07 DOWN synapsin II 
TCF25 13059029 -1.827271 4.2207E-06 DOWN transcription factor 25 (basic helix-loop-helix) 
TRIAP1 12960177 -1.455814 9.1656E-05 DOWN TP53 regulated inhibitor of apoptosis 1 
TRIB2 13098805 -1.65455 4.836E-07 DOWN tribbles homolog 2 (Drosophila) 
TTC26 13218326 -1.583521 0.00509751 DOWN tetratricopeptide repeat domain 26 
TUBB 13030037 -4.01288 2.33E-15 DOWN tubulin, beta 
UBAC1 13198301 -1.918137 3.9775E-06 DOWN UBA domain containing 1 
 





Table 2. Significant subnetworks (p ≤0.05) formed by over-expressed genes after blockage of PS1IV formation under mimicry of hypoxia. It should 

















1Total number of genes in pathway. 2Number of overlapping genes between sample and pathway. 3Percentage of overlap between sample and pathway. 4Central gene in 
pathway. 5Shared members between pathway and sample. 6Statistical significance based on “gene set enrichment” approach and Fisher’s exact test.  
Name 







Overlapping Entities5 p-value6 
Neighbours of PDLIM5 67 2 2 PDLIM5 AGTR1,PKD1 0.00175519 
Neighbours of MIR20A 264 3 1 MIR20A AGTR1,PKD1,CAMTA1 0.00177078 
Neighbours of LPS 2721 8 0 LPS HRH2,AGTR1,NOTCH2,IL17RA,CD22,PIM3,ANGPTL2,NLRC3 0.00235013 
Neighbours of BTK 298 3 1 BTK PKD1,NOTCH2,CD22 0.00249463 
Neighbours of ADRBK2 124 2 1 ADRBK2 HRH2,AGTR1 0.0057829 
Neighbours of NOTCH2 184 2 1 NOTCH2 NOTCH2,FOXE3 0.0122797 
Neighbours of MIR1-1 582 3 0 MIR1-1 NOTCH2,MRC2,GAK 0.0156391 
Neighbours of DLL1 210 2 0 DLL1 NOTCH2,FOXE3 0.0157536 
Neighbours of CHRM3 214 2 0 CHRM3 HRH2,PKD1 0.0163214 
Neighbours of CCKBR 224 2 0 CCKBR HRH2,PKD1 0.0177791 
Neighbours of TCR 1762 5 0 TCR AGTR1,PKD1,NOTCH2,IL17RA,NLRC3 0.0201721 
Neighbours of GRK 245 2 0 GRK HRH2,AGTR1 0.0210128 
Neighbours of CD19 246 2 0 CD19 PKD1,CD22 0.0211725 
Neighbours of p70RSK 253 2 0 p70RSK RICTOR,IL17RA 0.0223048 
Neighbours of HRH3 266 2 0 HRH3 HRH2,AGTR1 0.024473 
Neighbours of MIR221 286 2 0 MIR221 ANGPTL2,HSPA4 0.0279705 
Neighbours of radiation 1312 4 0 radiation AGTR1,PKD1,OLFM4,HSPA4 0.0300081 
Neighbours of MIR146A 317 2 0 MIR146A AGTR1,NOTCH2 0.0337632 
Neighbours of ATF2 324 2 0 ATF2 PKD1,ANGPTL2 0.0351313 
Neighbours of NFATC1 344 2 0 NFATC1 CD22,ANGPTL2 0.0391576 
Neighbours of ESR2 875 3 0 ESR2 AGTR1,NOTCH2,CD22 0.0445307 
Neighbours of hypoxia 2205 5 0 hypoxia AGTR1,RICTOR,NOTCH2,ANGPTL2,POLR3G 0.0467763 
Neighbours of ARRB1 386 2 0 ARRB1 AGTR1,PKD1 0.0481522 
Neighbours of cortisol 904 3 0 cortisol HRH2,AGTR1,NOTCH2 0.0482578 
Neighbours of Na+ 915 3 0 Na+ HRH2,AGTR1,CD22 0.0497112 





Table  3. Significant subnetworks (p ≤0.05) formed by genes under-expressed after blockage of PS1IV formation under mimicry of hypoxia.  It 







Gene Set Seed4 Overlapping Entities5 
p-
value6 
Neighbours of MEF2D 76 3 3 MEF2D CALR,TH,SMARCA4 0 
Neighbours of RPL28 15 2 12 RPL28 RPS19,RPL28 0 
Neighbours of mitogen-activated 
protein kinase kinase 
534 5 0 mitogen-activated 
protein kinase kinase 
IL1B,CCR5,HSPA8,CALR,TH 0.001 
Neighbours of TRIM22 32 2 6 TRIM22 IL1B,CCR5 0.001 
Neighbours of MAPKAPK2 316 4 1 MAPKAPK2 IL1B,HSPA8,TH,MAPKAPK5 0.001 
Neighbours of RAN 146 3 2 RAN IL1B,CCR5,HSPA8 0.001 
Neighbours of MECOM 156 3 1 MECOM CALR,TH,SMARCA4 0.002 
Neighbours of Ca2+ 3235 12 0 Ca2+ IL1B,CCR5,HSPA8,CALR,PLCB1,TH,RPS19,MAPKAPK5,CETN2, 
SLC25A5,SYN2,RAB3C 
0.002 
Neighbours of mitogen 610 5 0 mitogen IL1B,CCR5,HSPA8,TH,SLC25A5 0.002 
Neighbours of casein kinase II 909 6 0 casein kinase II IL1B,HSPA8,CALR,TH,EEF1B2,UBAC1 0.002 
Neighbours of MEF2A 381 4 1 MEF2A HSPA8,CALR,TH,SGCG 0.002 
Neighbours of RNA polymerase II 642 5 0 RNA polymerase II IL1B,CCR5,HSPA8,CALR,TH 0.002 
Neighbours of CASP5 50 2 3 CASP5 IL1B,NLRP12 0.003 
Neighbours of RPS6KA5 190 3 1 RPS6KA5 TH,SMARCA4,RPL26 0.003 
Neighbours of MAPKAPK3 52 2 3 MAPKAPK3 TH,MAPKAPK5 0.003 
Neighbours of HOXA2 55 2 3 HOXA2 NKX3-2,GBX2 0.003 
Neighbours of glyceraldehyde 55 2 3 glyceraldehyde HSPA8,PLCB1 0.003 
Neighbours of HAND2 200 3 1 HAND2 IL1B,TH,NKX3-2 0.003 
Neighbours of MAPKAPK5 57 2 3 MAPKAPK5 TH,MAPKAPK5 0.003 
Neighbours of KDM6A 57 2 3 KDM6A IL1B,SMARCA4 0.003 
Neighbours of NLRP12 57 2 3 NLRP12 IL1B,NLRP12 0.003 
Neighbours of glycerol 427 4 0 glycerol IL1B,CCR5,HSPA8,POP7 0.003 
Neighbours of endo-RNase 59 2 3 endo-RNase IL1B,CALR 0.003 
Neighbours of LRRK2 208 3 1 LRRK2 IL1B,TH,TUBB 0.003 
Neighbours of E2 209 3 1 E2 HSPA8,TH,CETN2 0.004 
Neighbours of ZFP42 60 2 3 ZFP42 CCR5,SMARCA4 0.004 
Neighbours of RCVRN 62 2 3 RCVRN HSPA8,TH 0.004 
Neighbours of galactosidase 62 2 3 galactosidase IL1B,TH 0.004 
Neighbours of STAT4 215 3 1 STAT4 IL1B,CCR5,SMARCA4 0.004 
Neighbours of dehydroascorbate 66 2 2 dehydroascorbate IL1B,TH 0.004 
Neighbours of RPS19 67 2 2 RPS19 IL1B,RPS19 0.004 
Neighbours of diterpenoids 69 2 2 diterpenoids IL1B,MAPKAPK5 0.005 
Neighbours of CCL16 70 2 2 CCL16 IL1B,CCR5 0.005 
Neighbours of FRK 70 2 2 FRK IL1B,TH 0.005 





Neighbours of LAG3 72 2 2 LAG3 IL1B,CCR5 0.005 
Neighbours of SNCA 479 4 0 SNCA IL1B,CALR,PLCB1,TH 0.005 
Neighbours of POLR2A 73 2 2 POLR2A SSU72,RPL28 0.005 
Neighbours of butanoic acid 780 5 0 butanoic acid IL1B,CCR5,HSPA8,TH,SLC25A5 0.005 
Neighbours of MAPK11 244 3 1 MAPK11 CALR,TH,MAPKAPK5 0.005 
Neighbours of melanin 76 2 2 melanin IL1B,TH 0.006 
Neighbours of MIR125B1 495 4 0 MIR125B1 CCR5,TRIB2,TRIAP1,SYN2 0.006 
Neighbours of mitogen-activated 
protein kinase 
2810 10 0 mitogen-activated 
protein kinase 
IL1B,CCR5,HSPA8,CALR,PLCB1,TH,MAPKAPK5,POU4F2,GORASP1,SYN2 0.006 
Neighbours of LILRB4 80 2 2 LILRB4 IL1B,NLRC3 0.006 
Neighbours of pathogen 261 3 1 pathogen IL1B,CCR5,HSPA8 0.007 
Neighbours of 5-
hydroxytryptophan 
83 2 2 5-hydroxytryptophan IL1B,TH 0.007 
 
1Total number of genes in the subnetwork. 2Number of overlapping genes between the sample and subnetwork. 3Percentage of overlap between the sample and 
subnetwork. 4Central gene in the subnetwork. 5Shared members between the subnetwork and sample. 6Statistical significance based on “gene set enrichment” 











Figure 1. Microarray comparisons to detect statistically significant changes in gene expression after morpholino-
inhibition of the induction of PS1IV that occurs under mimicry of hypoxia using NaN3. “MoCont” and “MoHmga1BB” 
represent embryos injected with the negative control and PS1IV-inhibiting morpholinos respectively. “Uninjected” 
represents uninjected embryos. Comparison A is of primary interest but genes for which expression was significantly 
altered by the act of injection itself (D), by PS1IV-independent differential effects of MoCont and MoHmga1BB 
injection (C), and by cellular responses to hypoxia (B) were subtracted from the set of genes seen in A before gene 






Figure 2. Comparison of the results of microarray and qPCR analyses for validation of nodal genes in the networks 
identified after failure to form PS1IV under mimicry of hypoxia. CAMTA1 and PKD1 are found to be over-expressed 
by both methods. IL1B, MAPKAPK5 and SMARCA4 are found to be under-expressed by both methods. Error bars 







Figure 3. Schematic representation of some of the subnetworks for genes over-expressed after failure to form PS1IV 
under mimicry of hypoxia.  (A) Neighbours of GABARAP (Gamma-Aminobutyric Acid Receptor-Associated Protein), 
(B) Neighbours of PDLIM5 (PDZ And LIM Domain 5), (C) Neighbours of MIR20A (microRNA 20a), (D) Neighbours of 







Figure 4. qPCR analysis supports upregulation of miR-20A by the presence of PS1IV under hypoxia. This is 
indicated by decreased expression of miR-20A in embryos injected with the Hmga1aBindBlock morpholino. Values 
are normalised against those for Hmga1aBindBlock in normoxia. The letters represent the significant difference at 
P<0.1 calculated using a Bayesian t-test. The microRNA expression is slightly different in MoHmga1aBindBlock 








Figure 5. Regulatory network for genes over-expressed after failure to form PS1IV under mimicry of hypoxia. This 
network was predicted using the union selected subnetworks algorithm. Yellow, green, and blue structure represent 







Figure 6. Significant pathways generated by under-expressed genes after failure to form PS1IV under mimicry of 







Figure 7. Regulatory network for genes under-expressed genes after failure to form PS1IV under mimicry of hypoxia. 
The network was constructed using the union selected subnetworks algorithm. The central/important genes in the 








Figure 8. The 10 highest ranked genes (hubs) in the regulatory networks of genes (A) over-expressed, (B) under-
expressed, and (C) the combined set of these genes after failure to form PS1IV under mimicry of hypoxia according 






The supplementary files are shared in this link (59 MB): https://drive.google.com/folderview?id=0B2Npj-
saFbgeSG5GLUx4cENfZXM&usp=sharing 
Supplemental Data 1. Primers used for qPCR. 
Supplemental Data 2. List of all over-expressed genes after failure to form PS1IV under mimicry of hypoxia 
Supplemental Data 3. List of all under-expressed genes after failure to form PS1IV under mimicry of hypoxia 
Supplemental Data 4. Relationships underlying significant subnetworks of the over-expressed genes 
Supplemental Data 5. Relationships underlying the regulatory network of over-expressed genes after failure to form 
PS1IV under mimicry of hypoxia. This network was predicted based on the union selected subnetworks algorithm.  
Supplemental Data 6. Shortest path network using genes over-expressed after failure to form PS1IV under mimicry 
of hypoxia.  
Supplemental Data 7. Relationships underlying the shortest path network using genes over-expressed after failure 
to form PS1IV under mimicry of hypoxia.  
Supplemental Data 8. Relationships underlying significant subnetworks of under-expressed genes 
 
Supplemental Data 9. Relationships underpinning the regulatory network for genes under-expressed after failure to 
form PS1IV under mimicry of hypoxia. The network was constructed using the union selected subnetworks algorithm. 
 
Supplemental Data 10. Topological analysis of the regulatory networks of genes under-expressed, over-expressed, 
and the combined set of these genes after failure to form PS1IV under mimicry of hypoxia. 
 
 
Supplemental Data 11. Comparison of the gene relative expression values within different biological replicates of 
the treatments HMGA1aBindBlock in chemical Hypoxia, Control Morpholino in chemical Hypoxia, HMGA1aBindBlock 
in Normoxia, Control Morpholino in Normoxia, Control Morpholino in chemical Hypoxia, Uninjected in chemical 
Hypoxia, Control Morpholino, Uninjected in Normoxia 
 
Supplemental Data 12. Subnetworks enriched by over- and under-expressed genes after failure to form PS1IV 
under mimicry of hypoxia 
 
Supplemental Data 13. Regulatory network underlying over- and under-expressed genes after failure to form PS1IV 
under mimicry of hypoxia. The network was constructed using the union selected subnetworks algorithm. 
Supplemental Data 14. Relationships underlying the regulatory network of over- and under-expressed genes after 
failure to form PS1IV under mimicry of hypoxia. The network was constructed using the union selected subnetworks 
algorithm. 
 
Supplemental Data 15. Network of interaction between under-expressed genes (after failure to form PS1IV under 






Supplemental Data 16. Relationships underlying the network of interaction between under-expressed genes (after 
failure to form PS1IV under mimicry of hypoxia) with other diseases 
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